Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,7.424399795816903,7.700399974139768,7.295599917321654,7.3968000411987305,28381,0.0,0.0,,,,,,,,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-06-28,7.360000096209265,7.677400346024797,7.212800234665941,7.295599937438965,55011,0.0,0.0,,,,,,,0.0,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-06-29,7.26800032135129,7.26800032135129,7.056400297002284,7.120800018310547,25162,0.0,0.0,,,,,,,0.0,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-06-30,7.120799808638702,7.360000019855288,7.070199966430664,7.070199966430664,14555,0.0,0.0,,,,,,,0.0,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-01,7.2312001607870755,7.26800012588501,7.143799914661841,7.26800012588501,46775,0.0,0.0,,,,,,,41.50820032357305,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-04,7.272600309753421,7.447400365201892,7.03340009534282,7.130000114440918,50428,0.0,0.0,,,,,,,31.640526697656384,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-05,7.171400013262097,7.26800003004287,7.038000031868667,7.208199977874756,38756,0.0,0.0,,,,,,,40.30131099472291,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-06,7.208200035095215,7.268000087738037,7.106999912261963,7.235799789428711,14915,0.0,0.0,,,,,,,43.044037571633886,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-07,7.240399989779799,7.295599937861744,7.134600198961952,7.263400077819824,18471,0.0,0.0,,,,,,,45.72923280944773,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-08,7.286400245730538,7.360000177313239,6.973600097813863,7.125400066375732,49580,0.0,0.0,7.211420011520386,,,-1.1928294983128835,,,36.47089062239826,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-11,7.13,7.291000175476075,6.9,7.17140007019043,23400,0.0,0.0,7.1888800144195555,,,-0.24315253828223982,,,40.7752264718511,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-12,7.084000111932618,7.13000028927499,6.858600208073445,7.05180025100708,25879,0.0,0.0,7.164500045776367,,,-1.5730308332641576,,,34.27324223313809,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-13,7.401400249310505,7.401400249310505,6.904600272382746,7.093200206756592,5090,0.0,0.0,7.161740064620972,,,-0.9570280022164878,,,37.96104785164482,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-14,6.9000000377692805,7.074800091368925,6.794200247761442,6.968999862670898,21079,0.0,0.0,7.1516200542449955,,,-2.5535499675447517,,,32.13570774039698,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-15,6.973600120922622,6.9920001038792705,6.7620000975760695,6.9598002433776855,21547,0.0,0.0,7.1208000659942625,,,-2.2609794001300454,,,31.747093416338387,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-18,6.936799964904785,6.991999912261964,6.633200035095215,6.808000087738037,62759,0.0,0.0,7.088600063323975,,,-3.9584681471556937,,,26.13164193845367,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-19,6.8080003304456325,7.130000254187006,6.711400309454201,6.9552001953125,50970,0.0,0.0,7.063300085067749,,,-1.5304445295164368,,,37.64881772975714,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-20,7.005799828134799,7.134600144703336,6.794200248108318,6.904600143432617,59125,0.0,0.0,7.03018012046814,,,-1.7862981443377364,,,35.594364264151466,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-21,6.90460033027034,7.033400211634001,6.7620001326000665,7.024200439453125,44590,0.0,0.0,7.00626015663147,,,0.2560607573881578,,,43.44939990043121,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-22,7.005799751653784,7.0839997863273485,6.8448000157359985,7.07480001449585,53030,0.0,0.0,7.001200151443482,,,1.0512463786254338,,,46.42637121957085,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-25,7.129999982485838,7.810799770242229,7.129999982485838,7.76479959487915,172249,0.0,0.0,7.060540103912354,,,9.974583822228492,,,69.78497958351832,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-26,7.718800296737871,7.870600261266655,7.406000157131801,7.700399875640869,50808,0.0,0.0,7.125400066375732,,,8.069719649546709,,,66.855096747776,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-27,7.815400220810996,7.815400220810996,7.295600146479577,7.314000129699707,51397,0.0,0.0,7.147480058670044,,,2.329773146098826,,,52.588597237752786,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-28,7.668200304060197,7.668200304060197,7.286400325763636,7.61299991607666,62266,0.0,0.0,7.21188006401062,,,5.5619318195229726,,,59.74677269115901,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-07-29,7.764799784402278,8.022400421770886,7.543999990126662,7.820000171661377,83871,0.0,0.0,7.297900056838989,,,7.154114344620533,,,63.81944481425473,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-01,8.00859966807999,9.439199902088166,8.00859966807999,9.33799934387207,416769,0.0,0.0,7.550899982452393,,,23.66736899671211,,,79.88887431746582,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-02,9.429999789328406,9.705999958638477,8.390399707268022,8.537599563598633,383908,0.0,0.0,7.7091399192810055,,,10.74646008493894,,,63.7988058763006,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-03,8.54219971370992,9.199999842854902,8.54219971370992,8.933199882507324,166079,0.0,0.0,7.911999893188477,,,12.906976783430055,,,67.30391613569208,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-04,9.029799613952637,9.112599754333496,8.473200035095216,8.65719985961914,166555,0.0,0.0,8.075299835205078,,,7.20592468749224,,,62.73977649406085,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-05,8.652600351623605,8.652600351623605,8.192600319869744,8.289200782775879,161926,0.0,0.0,8.196739912033081,,,1.1280200632822603,,,57.17267200277933,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-08,8.28460044502425,8.464000171619436,8.114400051997233,8.372000694274902,59066,0.0,0.0,8.257460021972657,,,1.3871174913043378,,,58.07411134617721,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-09,8.316800592615607,8.418000284396724,8.086800575256348,8.086800575256348,42539,0.0,0.0,8.296100091934203,,,-2.5228663391048642,,,53.868268340263256,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-10,8.096000324012962,8.40880047013275,7.957999795052852,8.316800117492676,56931,0.0,0.0,8.396380090713501,,,-0.947789075304511,,,56.59813141901831,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-11,8.316799811468238,8.532999491622638,8.192599603188317,8.27079963684082,60768,0.0,0.0,8.462160062789916,,,-2.261366182265356,,,55.88583148230145,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-12,8.270800128601387,8.523800665404769,8.105200718429064,8.372000694274902,53530,0.0,0.0,8.51736011505127,,,-1.706625278406378,,,57.16311143334881,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-15,8.372000506357834,8.413400577316754,8.003999973098582,8.220200538635254,69149,0.0,0.0,8.405580234527587,,,-2.2054360403443587,,,54.608976235421636,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-16,7.994799576600842,8.220200347642493,7.893599892930581,8.164999961853027,123485,0.0,0.0,8.368320274353028,,,-2.4296430566015808,,,53.66987016234837,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-17,8.187999382916137,8.666399788509432,8.10979935036263,8.21560001373291,37636,0.0,0.0,8.296560287475586,,,-0.9758293911862811,,,54.44325443473393,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-18,8.229400032827861,8.229400032827861,7.902800441525033,8.008600234985352,51696,0.0,0.0,8.231700325012207,,,-2.7102552476182975,,,50.71366985736026,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-19,8.00859992980957,8.10060028076172,7.90280014038086,7.994799613952637,30833,0.0,0.0,8.202260208129882,7.652905070781708,,-2.5293100793317365,7.178386929763131,,50.46545714160019,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-22,7.994799916172298,8.07760005968317,7.8752006837459305,8.072999954223633,40222,0.0,0.0,8.172360134124755,7.6698100686073305,,-1.2158076525070274,6.552314347057576,,51.902006789021286,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-23,8.05920038748349,8.05920038748349,7.571599745066017,7.820000171661377,56676,0.0,0.0,8.14568009376526,7.68292007446289,,-3.9981919048497754,6.023230943668515,,47.13892196955133,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-24,7.746400224612317,7.7970005063827355,7.543999974911032,7.654399871826172,24959,0.0,0.0,8.079440069198608,7.696260070800781,,-5.260763044617709,4.978781835239589,,44.27483147321048,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-25,7.654399575788434,8.463999665901497,7.654399575788434,8.142000198364258,214318,0.0,0.0,8.066560125350952,7.723055076599121,,0.9352198687048632,4.447787117207694,,53.27662153846531,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-26,8.14659965597875,8.197199937219485,7.87520046059944,8.059200286865234,41689,0.0,0.0,8.035280084609985,7.742835080623626,,0.29768971340605627,3.776975758119911,,51.747925971615636,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-29,8.040799847479414,8.040799847479414,7.727999704840289,7.92579984664917,44176,0.0,0.0,8.005840015411376,7.762730073928833,,-0.9997722738416913,3.1317582753396125,,49.29384387007744,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-30,7.833800372643907,7.916599636244605,7.645200441467182,7.893599987030029,37671,0.0,0.0,7.978700017929077,7.779865074157715,,-1.0665901802025108,2.5557633953296928,,48.693570387603145,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-08-31,7.898200167072315,8.358200174758808,7.773999954425669,7.990200519561768,42655,0.0,0.0,7.956160068511963,7.798725092411042,,0.4278502538495465,2.018727089817817,,50.635706332357636,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-01,7.999399911076279,8.045400087655509,7.732599939773217,7.953400611877441,28437,0.0,0.0,7.950640106201172,7.815975105762481,,0.03472054626288637,1.7229456160806664,,49.86138001663211,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-02,7.815399968405891,8.096000251813393,7.783200108483137,8.091400146484375,32684,0.0,0.0,7.960300159454346,7.840125107765198,,1.6469226587432555,1.5328205868822324,,52.777666384195484,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-05,7.948800622452136,7.999400027785166,7.682000647256541,7.91200065612793,43924,0.0,0.0,7.944200229644776,7.858640122413635,,-0.40532177671817926,1.0887393480090075,,48.80357631172278,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-06,7.994799387416974,8.224799380899837,7.81999977841735,8.07759952545166,45782,0.0,0.0,7.969960165023804,7.88428510427475,,1.3505633428411845,1.0866560457409402,,52.368900113119516,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-07,8.077599871033991,8.077599871033991,7.654399829824627,7.921199798583984,47627,0.0,0.0,7.996640157699585,7.904985094070435,,-0.9434006986417017,1.1594590317178597,,48.90492131715079,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-08,7.921200055477619,8.367400637918303,7.567000705682341,8.13740062713623,67631,0.0,0.0,7.996180200576783,7.934195113182068,,1.7660985997947038,0.7812397667374095,,53.48526792058729,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-09,8.137400854984781,8.41800027937706,8.004000423853348,8.151200294494629,37931,0.0,0.0,8.005380201339722,7.963980114459991,,1.821526142262464,0.5198416656586351,,53.77013211874561,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-12,8.155800123885415,8.721599936516698,7.971800291815942,8.372000694274902,43664,0.0,0.0,8.050000286102295,8.003080129623413,,4.000004928304372,0.5862762301380245,,58.182956022569066,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-13,8.279999735032044,8.509999727671824,8.187999387023996,8.344399452209473,35030,0.0,0.0,8.095080232620239,8.037810111045838,,3.079885713603772,0.712509014062158,,57.444783297839315,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-14,8.187999382916137,8.330600009995106,8.003999564372693,8.21560001373291,9531,0.0,0.0,8.117620182037353,8.070585107803344,,1.2070019229572584,0.5827963351570487,,54.00175856866229,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-15,8.234000017305075,8.23860012269842,8.004000011920127,8.146599769592285,16236,0.0,0.0,8.136940097808838,8.098645091056824,,0.11871381216200463,0.4728569572001894,,52.19685009760698,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-16,8.137400617091162,8.142000722586774,7.8752007455041335,7.939600467681885,16353,0.0,0.0,8.121760129928589,8.120265102386474,,-2.2428594212656927,0.018411068151891218,,47.1098479633181,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-19,7.73260010158109,7.8200003511724745,7.497999985760266,7.645200729370117,46894,0.0,0.0,8.095080137252808,8.117275130748748,,-5.557442301434264,-0.2734291143078842,,40.99112630014869,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-20,7.645200347007786,7.718800276441525,7.4520003128991315,7.470399856567383,26871,0.0,0.0,8.03436017036438,8.111525130271911,,-7.019355640505472,-0.9513002631225818,,37.847859946823,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-21,7.364600369182625,7.470400162402478,7.180600099375201,7.452000617980957,45046,0.0,0.0,7.9874402523040775,8.114975142478944,,-6.70351974362082,-1.571599270924039,,37.52171180146762,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-22,7.185200247158799,7.447400556408402,6.992000204002335,7.314000129699707,34804,0.0,0.0,7.9051002025604244,8.107500147819518,,-7.477451995728819,-2.4964531800043024,,35.07997780168647,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-23,7.313999766203076,7.359999941312351,7.0839997680370645,7.176000118255615,41113,0.0,0.0,7.807580184936524,8.091400146484375,,-8.0893189915544,-3.507674276511563,,32.7825512362828,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-26,7.015000018838775,7.447400265666489,7.015000018838775,7.102399826049805,15146,0.0,0.0,7.680620098114014,8.035510158538818,,-7.528301942784438,-4.416521831506681,,31.594120966753138,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-27,7.014999944063335,7.474999940395357,6.899999944980329,7.176000118255615,34591,0.0,0.0,7.563780164718628,8.001470172405243,,-5.1268021811609295,-5.470119843676753,,34.164378150169554,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-28,7.176000232769988,7.3416000761636875,6.900000055090301,7.166800022125244,31741,0.0,0.0,7.4589001655578615,7.957310175895691,,-3.916128878911879,-6.263548854079036,,33.9924436423464,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-29,6.9506000439953635,7.438200251184455,6.9506000439953635,7.2220001220703125,22307,0.0,0.0,7.366440200805664,7.92143018245697,,-1.9607853291139805,-7.0061840964072735,,36.0712680249035,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-09-30,7.222000064076278,7.295599995432999,6.92300023326705,7.258800029754639,16588,0.0,0.0,7.298360157012939,7.895670163631439,,-0.5420413134899567,-7.565032406872733,,37.48478626080525,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-03,7.258800209837626,7.912000713559212,7.226600348742766,7.907400608062744,72827,0.0,0.0,7.324580144882202,7.884055161476136,,7.957049436994248,-7.096284908402168,,55.96534835009528,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-04,7.912000764320299,8.712400700852124,7.732600158328734,8.031599998474121,92973,0.0,0.0,7.380700159072876,7.882675147056579,,8.818944346372254,-6.368079092681407,,58.49552693946541,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-05,8.031599319839492,8.298400153520358,7.746399820370142,8.279999732971191,27987,0.0,0.0,7.463500070571899,7.881755137443543,,10.939902923277215,-5.306623456045415,,63.06635727913293,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-06,8.27999992450297,8.73999992030869,8.151199609820438,8.367400169372559,56328,0.0,0.0,7.568840074539184,7.884170150756836,,10.550627136642111,-3.999534132167116,,64.54585522967812,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-07,8.74000035841385,8.74000035841385,8.16500033483399,8.372000694274902,29387,0.0,0.0,7.688440132141113,7.884170150756836,,8.890757427845484,-2.482569691839204,,64.62618058340146,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-10,8.372000673870707,8.43180029012989,7.861400373414495,7.91200065612793,17879,0.0,0.0,7.769400215148925,7.876465153694153,,1.835411190441177,-1.359301875347127,,51.95192542604184,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-11,8.00400000022439,8.050000176710242,7.820000171661377,7.820000171661377,17919,0.0,0.0,7.833800220489502,7.867840158939361,,-0.17616033648689405,-0.43264654291665106,,49.84638048995274,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-12,7.553200372863906,7.953400776807679,7.553200372863906,7.677400588989258,13320,0.0,0.0,7.884860277175903,7.85438517332077,,-2.6311143240822363,0.38800113799676045,,46.687887523377725,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-13,7.562400282996045,7.9625997936385025,7.401400106725241,7.727999687194824,16889,0.0,0.0,7.935460233688355,7.847370159626007,,-2.6143480073505985,1.1225426132637768,,47.94823685786464,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-14,7.820000155236043,8.091400230814077,7.46579993763347,7.6865997314453125,43342,0.0,0.0,7.978240203857422,7.839665162563324,,-3.6554486322823854,1.7676142848017833,,46.96981603358289,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-17,7.691199779510498,8.091400170520167,7.364600196603388,7.691199779510498,44737,0.0,0.0,7.956620121002198,7.830120158195496,,-3.335842825914225,1.6155558312128713,,47.09898679261449,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-18,7.521000453253544,7.746400356292725,7.3646003772867,7.746400356292725,29009,0.0,0.0,7.928100156784057,7.8282801628112795,,-2.2918454219558857,1.2751203571760106,,48.71338635679894,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-19,7.727999861896899,7.935000218550371,7.406000379456425,7.617599964141846,34417,0.0,0.0,7.861860179901123,7.827360165119171,,-3.106901040846922,0.440761815659045,,45.243898928836316,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-20,7.6175998925209,7.6175998925209,7.281800097000598,7.360000133514404,60558,0.0,0.0,7.761120176315307,7.8078101634979244,,-5.168326655023399,-0.5979908092655255,,39.2264901050915,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-21,7.360000149871462,7.5347997673835385,7.189800199048508,7.493400573730469,47482,0.0,0.0,7.673260164260864,7.793665170669556,,-2.3439787871146796,-1.5449086376178927,,43.42297779650045,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-24,7.493400689654882,7.5302006558783265,7.2680003481735325,7.452000617980957,40880,0.0,0.0,7.627260160446167,7.7818201899528505,,-2.29780470022617,-1.9861680909337462,,42.44346577253991,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-25,7.452000313062449,7.521000137235545,7.387599716771241,7.502599716186523,16640,0.0,0.0,7.595520114898681,7.7720451831817625,,-1.223357943979289,-2.271282064405272,,44.10307436351481,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-26,7.5025998904347375,7.534799750638001,7.360000133514404,7.360000133514404,40762,0.0,0.0,7.563780069351196,7.756290173530578,,-2.6941546947209396,-2.481986876101536,,40.55407666064854,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-27,7.442800463034806,7.525600607005147,7.332400124844284,7.479600429534912,18730,0.0,0.0,7.538940143585205,7.744445168972016,,-0.7871094997455924,-2.6535797065251723,,44.58204486593136,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-28,7.277199767568329,7.5439997290983065,7.277199767568329,7.53939962387085,35662,0.0,0.0,7.524220132827759,7.730645155906677,,0.2017417190768141,-2.6702172834979576,,46.532784403658034,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-10-31,7.539399883388221,8.275400074888699,7.28180012344619,7.884399890899658,105406,0.0,0.0,7.543540143966675,7.7299551367759705,,4.518564764391195,-2.411592169822679,,56.127823554686906,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-01,7.912000510013472,8.137400409259223,7.553200186943286,7.590000152587891,45615,0.0,0.0,7.527900123596192,7.717765152454376,,0.8249316273079449,-2.4601037360900295,,48.181878100757345,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-02,7.5899999254677235,7.925799711598948,7.45659950563511,7.769399642944336,42005,0.0,0.0,7.54308009147644,7.713970148563385,,3.0003599156216434,-2.2153321026108808,,52.58677124015747,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-03,7.769400062357881,8.004000178004157,7.544000157689201,7.77400016784668,40172,0.0,0.0,7.584480094909668,7.704885137081146,,2.498787926995926,-1.5627104107238106,,52.69781796344614,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-04,7.769399891922045,7.971800142087125,7.54399999219792,7.723400592803955,15608,0.0,0.0,7.607480096817016,7.694190144538879,,1.5237699541986314,-1.1269548333609527,,51.27536107939777,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-07,7.727999629825622,7.727999629825622,7.452000332416426,7.6682000160217285,37413,0.0,0.0,7.629100036621094,7.67659512758255,,0.5125110329258686,-0.6186999597100353,,49.69928193575612,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-08,7.6635999108272355,8.75840039944848,7.3967999465833,7.700399875640869,59195,0.0,0.0,7.648880052566528,7.660495138168335,,0.6735603476623206,-0.1516231704649798,,50.65214958042229,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-09,7.700400120228301,7.820000229016555,7.26800030058872,7.815400123596191,134527,0.0,0.0,7.694420051574707,7.650490140914917,,1.5723091696394316,0.5742104080999054,,54.003448380487924,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-10,7.815400036489962,7.815400036489962,7.286400202369691,7.360000133514404,76364,0.0,0.0,7.682460021972656,7.63082515001297,,-4.1973519879827865,0.6766617101637937,,41.875575776187766,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-11,7.3875998898734,8.445600435712702,7.3875998898734,8.316800117492676,286232,0.0,0.0,7.760200071334839,7.64025514125824,,7.17249608310802,1.5699073899886271,,61.45930816991407,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-14,8.321399801826475,8.417999377568574,8.013199776670666,8.279999732971191,54968,0.0,0.0,7.799760055541992,7.656125116348266,,6.157108347044248,1.8760787867353368,,60.6134036326697,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-15,8.280000629949988,8.280000629949988,7.9120009529043855,8.022400856018066,53304,0.0,0.0,7.84300012588501,7.6699251413345335,,2.2873993019707206,2.2565407270762767,,54.915620984834156,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-16,8.022400130962497,8.183400304136597,7.9442000969853845,8.003999710083008,9201,0.0,0.0,7.866460132598877,7.683725118637085,,1.7484303634129204,2.3782086311047625,,54.52135488746292,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-17,7.833800487821249,8.123600108135447,7.543999990126662,7.820000171661377,84424,0.0,0.0,7.871060132980347,7.6963751196861265,,-0.6487050086814172,2.2697050309749476,,50.608668882500325,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-18,7.820000187535714,7.962599945288973,7.64060046399515,7.953400611877441,31774,0.0,0.0,7.894060134887695,7.7158101320266725,,0.7517104756713422,2.3101916689362954,,53.229308834382344,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-21,7.912000700369412,7.912000700369412,7.544000157689201,7.77400016784668,32100,0.0,0.0,7.904640150070191,7.732600140571594,,-1.652699929956342,2.2248662334928304,,49.430864493698145,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-22,7.548599833916214,7.727999550875498,7.456599484132789,7.507199764251709,96719,0.0,0.0,7.885320138931275,7.740880131721497,,-4.79524442910968,1.865937784230434,,44.36092071606711,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-23,7.50719993068747,8.463999904649983,7.50719993068747,8.059200286865234,136820,0.0,0.0,7.909700155258179,7.763190138339996,,1.890085953608135,1.8872398370692336,,54.710838648324284,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-24,8.096000460414734,9.080400214298956,8.096000460414734,8.671000480651855,219304,0.0,0.0,8.040800189971923,7.799415147304535,,7.83753203401181,3.0949120941563315,,62.93940481777728,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-25,8.671000597105863,8.970000436168739,8.629600524902344,8.629600524902344,64057,0.0,0.0,8.07208023071289,7.8336851596832275,,6.906773449403832,3.043204649793492,,62.116944558064404,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-28,8.634200510004106,9.01600048814966,8.556000472196926,8.799799919128418,115971,0.0,0.0,8.124060249328613,7.85599514245987,,8.317757981369592,3.412236158598319,,64.18877533616742,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-29,8.799799534932433,8.91479953389976,8.197199786010147,8.496199607849121,68997,0.0,0.0,8.171440124511719,7.867610132694244,,3.9743237224883687,3.861782506925376,,58.08622564633744,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-11-30,8.459399798061071,8.574399799132616,8.118999900174947,8.187999725341797,67107,0.0,0.0,8.189840126037598,7.8653101325035095,,-0.022471753629846655,4.126092780410068,,52.61737170106936,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-01,8.280000000000001,8.712400245666505,8.187999649047851,8.59280014038086,82005,0.0,0.0,8.267120122909546,7.870945131778717,,3.9394615371415824,5.033385247869204,,58.1858847643539,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-02,9.006800353924417,9.006800353924417,8.533000017603209,8.832000732421875,37912,0.0,0.0,8.35498013496399,7.882445132732391,,5.709416297253008,5.9947769286634776,,61.095439885666714,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-05,9.057400563262236,9.057400563262236,8.510000298401264,8.703200340270996,35039,0.0,0.0,8.44790015220642,7.902225124835968,,3.0220549895810063,6.905333861666965,,58.72585304190913,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-06,8.477800062781666,8.822800059623805,8.26159950323716,8.335200309753418,38615,0.0,0.0,8.530700206756592,7.915105128288269,,-2.291721573433463,7.777471915922003,,52.46480225082255,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-07,8.279999961768066,8.279999961768066,8.096000138093737,8.26159954071045,26708,0.0,0.0,8.550940132141113,7.929710102081299,,-3.383728420025954,7.834208591014703,,51.28707425542444,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-08,8.257000503625095,8.257000503625095,8.045400043474784,8.252400398254395,16450,0.0,0.0,8.509080123901366,7.942820119857788,,-3.0165390607379274,7.129205943212487,,51.132575742304944,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-09,8.017800623810563,8.252400743241317,8.013200518247556,8.224800109863281,19540,0.0,0.0,8.468600082397462,7.956275129318238,7.816281787554423,-2.878869826914304,6.439256369998411,1.7910477842127097,50.63967637584948,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-12,8.229399451760955,8.238599662033213,7.994799354100436,8.21560001373291,17356,0.0,0.0,8.41018009185791,7.969385135173797,7.823105120658875,-2.3136255823270355,5.531103707594875,1.8698459532217382,50.465048042436,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-13,8.23860043445499,8.23860043445499,7.994800103664364,8.096000671386719,14882,0.0,0.0,8.37016019821167,7.978125143051147,7.829775126775106,-3.275439422097638,4.913874477163098,1.8946906376498116,48.14092391959529,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-14,8.096000671386719,8.188000150593812,7.994800103664364,8.096000671386719,22138,0.0,0.0,8.360960292816163,7.990085160732269,7.837901798884074,-3.1690094456865263,4.641691854632301,1.9416339443020594,48.14092391959529,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-15,8.183401038785064,8.257000974149593,7.999400322993307,8.086800575256348,19878,0.0,0.0,8.310360336303711,8.008255171775819,7.846373470624288,-2.690133183163496,3.772421807844334,2.0631404018377784,47.94393796086819,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-16,8.183400190183516,8.183400190183516,7.842999427695877,8.1097993850708,38982,0.0,0.0,8.238140201568603,8.023665142059325,7.853388464450836,-1.5578858013774193,2.6730310364651046,2.1681937469318417,48.51113227818758,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-19,8.1097993513917,8.279999731928696,7.953400163645185,8.24779987335205,45151,0.0,0.0,8.19260015487671,8.043560123443603,7.862703462441762,0.6737753269025754,1.8529112624982687,2.3001841779452805,51.89789365497573,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-20,7.912000293194409,8.238599869667649,7.727999592633321,7.838400363922119,78466,0.0,0.0,8.14292016029358,8.051955139636993,7.86795513232549,-3.739687856161927,1.1297258750088788,2.3386001091381257,42.88562072471491,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-21,7.686599616800035,7.925799828552066,7.3553999310221005,7.727999687194824,83762,0.0,0.0,8.089560174942017,8.061155128479005,7.872056798140208,-4.4694702793255905,0.3523694310590927,2.4021464172295057,40.826707414710945,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-22,7.792400602792292,7.912000713559212,7.640600630930513,7.907400608062744,38334,0.0,0.0,8.055060195922852,8.071850132942199,7.877423469225565,-1.833128297847451,-0.20800605490462412,2.4681504615842096,45.412916670297996,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-23,7.9074006095444975,7.9074006095444975,7.760200743151603,7.8752007484436035,14888,0.0,0.0,8.020100259780884,8.080245161056519,7.883671808242798,-1.8067044880214427,-0.7443450053410338,2.4934238460839193,44.742625361333396,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-27,7.87060045142566,7.9304000666749745,7.727999816619679,7.916599750518799,29819,0.0,0.0,7.990200233459473,8.081050157546997,7.8898818055788675,-0.9211343995168894,-1.1242341319052243,2.4229558398828743,45.849272251601064,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-28,7.916599809751696,7.916599809751696,7.769399945839347,7.847599983215332,15677,0.0,0.0,7.965360164642334,8.087490153312682,7.896513470013937,-1.4784037255431461,-1.5101098901532914,2.4184937317457464,44.25832340622169,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-29,7.8153999509094785,7.9579997062683105,7.8153999509094785,7.9579997062683105,38592,0.0,0.0,7.951560068130493,8.092205154895783,7.903720132509867,0.08098584532647059,-1.7380316498797603,2.384763367450637,47.403094260423124,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2022-12-30,7.994799940550831,8.510000347644816,7.957999974142719,8.404200553894043,55042,0.0,0.0,7.983300065994262,8.107960164546967,7.91568013827006,5.272261901975252,-1.5375026026619558,2.429103032439209,57.77245344588962,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-02,8.372000931126161,8.372000931126161,8.013200590404606,8.257000923156738,37795,0.0,0.0,7.998020219802856,8.121300172805785,7.926490143934886,3.2380601228370693,-1.5179829630695427,2.4577085864411585,53.990875099667036,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-03,8.05920040152414,8.187999843052447,8.027000541142064,8.050000190734863,23553,0.0,0.0,7.978240251541138,8.130845177173615,7.936840144793193,0.899445703955379,-1.8768642411356913,2.4443610913304803,49.12149463710746,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-04,8.05000049309296,8.183400922406818,7.953400908318448,8.096000671386719,51864,0.0,0.0,8.004000282287597,8.140735197067261,7.946346815427145,1.1494301081262221,-1.679638404513189,2.4462609819990315,50.19644608154378,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-05,8.096000553509139,8.252400631002484,7.990200759140234,8.169600486755371,32720,0.0,0.0,8.048160362243653,8.14959020614624,7.956888484954834,1.5089178028985393,-1.244600542320402,2.4218225699125098,51.94582802602071,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-09,8.464000287827075,8.464000287827075,8.178800763548807,8.362800598144531,122346,0.0,0.0,8.09370036125183,8.174660217761993,7.968043486277263,3.324810962622292,-0.990375799770269,2.593067317473478,56.28648408338555,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-10,8.321400222862719,8.482400401292654,8.247800291702815,8.316800117492676,75384,0.0,0.0,8.137860298156738,8.174660217761993,7.978393487135569,2.198855875867864,-0.4501706324783401,2.4599780763243384,55.01232413285004,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-11,8.514600333427966,8.542200088500977,8.137400463702038,8.542200088500977,150911,0.0,0.0,8.200420331954955,8.181215226650238,7.9848718245824175,4.167832168482782,0.23474636435620033,2.4589424399193613,59.812794627289435,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-12,8.542199635917266,8.832000119661021,8.542199635917266,8.739999771118164,62787,0.0,0.0,8.289660310745239,8.199155199527741,7.993535157044729,5.43254419953958,1.103834590455254,2.5723292441117085,63.49416067941392,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-13,8.740000426576621,8.740000426576621,8.376599987697416,8.597400665283203,32019,0.0,0.0,8.353600406646729,8.213990223407745,8.004230161507925,2.918505156680575,1.6996633723903316,2.620615070622891,59.2782403480676,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-16,8.578999863379254,8.59740028460517,8.376599616796055,8.422599792480469,24361,0.0,0.0,8.35544033050537,8.229055213928223,8.010976827144622,0.803781240946715,1.5358399389911954,2.7222446336963286,54.50102562940437,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-17,8.399600680641154,8.606600168391973,8.192600315509901,8.35360050201416,70780,0.0,0.0,8.365100288391114,8.239060211181641,8.01542349656423,-0.1374733832290404,1.5297870628305035,2.790079834375216,52.69576109073965,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-18,8.358199958885157,8.459399642105485,8.197199784877082,8.367400169372559,32092,0.0,0.0,8.396840286254882,8.253895211219788,8.007335170110066,-0.3506094659263103,1.7318498887747436,3.079177227775933,53.03084808436688,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-19,8.445600008392324,8.445600008392324,8.146599316130757,8.279999732971191,44140,0.0,0.0,8.41524019241333,8.273215210437774,8.005188504854837,-1.6070897128291552,1.7166842438278713,3.3481623252268076,50.58672140641827,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-20,8.280000501201116,8.418000158602299,8.059200698407055,8.19260025024414,70334,0.0,0.0,8.417540168762207,8.276550209522247,7.999016841252645,-2.6722761520381706,1.7034870286626118,3.4695934985197594,48.194651184167135,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-23,8.192599906409049,8.247800293481072,8.114399869862241,8.220200538635254,36420,0.0,0.0,8.40328016281128,8.265280210971833,7.995375180244446,-2.1786685749958057,1.6696342811978417,3.3757644218408593,49.01457383916192,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-24,8.220200951293158,8.32140064239502,8.068400975950148,8.32140064239502,29666,0.0,0.0,8.403740215301514,8.25757521390915,7.995643512407939,-0.9797967428428013,1.7700716930336073,3.2759302124304965,52.01352344558089,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-25,8.243200532115305,8.252400743241317,8.096000663620813,8.224800109863281,18048,0.0,0.0,8.372000217437744,8.24320021867752,7.9944168408711755,-1.7582429975081102,1.5624999435096516,3.1119640463885814,49.04783063747078,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-26,8.224799927366925,8.266199999134946,8.004000129524416,8.008600234985352,26962,0.0,0.0,8.298860263824462,8.231010234355926,7.993765171368917,-3.4975890617701113,0.8243220156054789,2.967876312363343,43.1217582599436,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-27,8.261599540410755,8.261599540410755,8.013199997804515,8.197199821472168,23377,0.0,0.0,8.258840179443359,8.231240236759186,7.992768502235412,-0.7463561060863824,0.33530721847865247,2.9835936629101454,48.919660691143505,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-30,8.197199742415856,8.197199742415856,7.99020027180375,8.003999710083008,31359,0.0,0.0,8.216980171203613,8.21652022600174,7.990545169512431,-2.591955398249521,0.005597810134001692,2.8280305247695257,43.97453519692571,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-01-31,7.994799916172298,8.266199996622202,7.916599878120962,8.072999954223633,37629,0.0,0.0,8.18892011642456,8.197545206546783,7.9880534966786705,-1.4155732447362102,-0.10521552373184437,2.6225626800723925,46.071263068603685,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-01,8.003999595904876,8.160399661628036,7.971799737205464,8.013199806213379,22544,0.0,0.0,8.153500080108643,8.180295193195343,7.986328490575155,-1.7207367696916023,-0.32755679903813145,2.4287343408062014,44.516328033782926,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-02,8.004000085845691,8.178800582885742,7.912000609270232,8.178800582885742,43581,0.0,0.0,8.143380165100098,8.17638520002365,7.986443495750427,0.4349596490342551,-0.40366291602134446,2.37830148518914,49.59022541343618,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-03,8.178800812885779,8.178800812885779,8.040800278071211,8.160400390625,19990,0.0,0.0,8.140160179138183,8.173855221271515,7.985983498891195,0.248646353897174,-0.4122294953994761,2.3525182891550465,49.053452321565054,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-06,8.165000193459647,8.165000193459647,7.663600111389159,8.050000190734863,55650,0.0,0.0,8.123140144348145,8.168795216083527,7.9863284985224405,-0.9003901485581374,-0.5588960247833351,2.2847384451421595,45.846910479188374,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-07,8.050000039736432,8.050000039736432,7.727999687194824,7.727999687194824,47098,0.0,0.0,8.063800048828124,8.156375205516815,7.984105165799459,-4.164294248368676,-1.1350036548842737,2.157662457344475,38.037016281009954,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-08,7.727999687194824,7.935000039168768,7.727999687194824,7.727999687194824,42943,0.0,0.0,8.01412000656128,8.144185197353362,7.981230163574219,-3.570202581596039,-1.5970313498562176,2.0417282854823395,38.037016281009954,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-09,7.84300000125317,7.912000706256079,7.622200201909011,7.645200729370117,6835,0.0,0.0,7.977780055999756,8.132915198802948,7.979773501555125,-4.168820452495677,-1.9074973611679327,1.9191233588018257,36.198113782904166,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-10,7.626799888426337,7.7325996767941305,7.4335998552684535,7.608400344848633,24567,0.0,0.0,7.918900108337402,8.120725190639495,7.9793901721636455,-3.9209960883565125,-2.4853086093189183,1.7712508779041989,35.37943170633913,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-13,7.5670004447795645,7.99020048512227,7.553200128751513,7.691199779510498,31636,0.0,0.0,7.887620115280152,8.11083517074585,7.975633502006531,-2.490235747905022,-2.7520600624555818,1.6951840716515385,38.73672475471273,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-14,8.08219983968332,8.08219983968332,7.543999805915646,7.73259973526001,25862,0.0,0.0,7.853580093383789,8.10140517950058,7.972911830743154,-1.5404485175582314,-3.0590382856529126,1.6116238519277404,40.4039457614453,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-15,7.636000400962038,7.889000057480799,7.6175999792761075,7.75100040435791,4913,0.0,0.0,7.827360153198242,8.088985192775727,7.97145516872406,-0.9755491934165264,-3.2343369822353267,1.474386063322477,41.170262470323145,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-16,7.838400535785337,7.916599694643905,7.553200145566694,7.8246002197265625,20550,0.0,0.0,7.791940116882325,8.088640189170837,7.9708801706631975,0.41915238508411096,-3.6681081782539646,1.4773778552217474,44.25773561012264,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-17,7.557800277483466,7.631400208628179,7.083999953031537,7.360000133514404,218525,0.0,0.0,7.711900091171264,8.079440200328827,7.96562850077947,-4.563077237731879,-4.549078897107306,1.4287849293777668,32.61982240250288,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-20,7.360000307095133,7.52100048928892,7.084000120102984,7.314000129699707,67454,0.0,0.0,7.638300085067749,8.06460518836975,7.960300163427989,-4.245708492155502,-5.286124904375857,1.3103152243048608,31.730167545062045,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-21,7.217399923345594,7.304800170421291,6.992000024997018,7.097800254821777,22166,0.0,0.0,7.5752801418304445,8.045170176029206,7.952020164330801,-6.303131739934463,-5.840647542780526,1.1714005972499244,27.88128232330058,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-22,7.097800140380859,7.447400245666504,6.9092002105712895,7.235799789428711,34998,0.0,0.0,7.526060152053833,8.028150177001953,7.946385157108307,-3.856737213904821,-6.254118494026745,1.0289586809230378,33.43183285925737,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-23,7.028800138383147,7.217400075201794,6.9138001341093185,7.185200214385986,41364,0.0,0.0,7.48006010055542,8.01159018278122,7.93894849618276,-3.941945414951135,-6.634514123902418,0.9150038778232119,32.445779959289965,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-24,7.1622001161416815,7.235800048587319,6.872400053119333,6.923000335693359,34359,0.0,0.0,7.411520099639892,7.9857151985168455,7.930630167325337,-6.591357203096148,-7.190277697150986,0.6945858025061068,27.86019739619256,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-27,6.899999981040272,7.208200015288619,6.899999981040272,6.941400051116943,7731,0.0,0.0,7.3365401268005375,7.949145185947418,7.92066349585851,-5.3859185509002945,-7.706552652099627,0.359587174784035,28.622558236626304,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-02-28,7.125399894714356,7.139200210571289,6.775799789428711,7.139200210571289,22998,0.0,0.0,7.277200174331665,7.921200168132782,7.912230161825816,-1.8963332113239555,-8.130081049989716,0.11336887481160304,36.40329081182824,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-01,7.13920013215526,7.194400078906129,6.886200047196142,6.946000099182129,32115,0.0,0.0,7.196700143814087,7.893600165843964,7.9003468235333765,-3.483541617993445,-8.828671422266877,-0.08539698117196648,32.65854950681191,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-02,6.946000099882989,7.051799888160284,6.752800066890363,7.01039981842041,39938,0.0,0.0,7.115280103683472,7.866460144519806,7.889230159918467,-1.4740148488148312,-9.549149516249008,-0.28862151232886246,35.05670202606632,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-03,7.010400155246942,7.185200214385986,6.808000340748693,7.185200214385986,25406,0.0,0.0,7.0978001117706295,7.841850137710571,7.88064349492391,1.2313688923194235,-9.48819491412988,-0.49226128853978246,41.17970733653539,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-06,7.185200265783736,7.185200265783736,6.844800355983876,6.886200428009033,18055,0.0,0.0,7.055020141601562,7.8049351334571835,7.870140167077382,-2.3929019365521658,-9.608215558909425,-0.8285117194350178,35.08605125475002,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-07,6.959800358222552,7.143800190825246,6.817200158937809,6.9506001472473145,17981,0.0,0.0,7.040300130844116,7.77078013420105,7.861898497740428,-1.2740931768493644,-9.400343218332964,-1.158986771014229,37.240191971044986,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-08,6.950600053700651,7.125400111665716,6.762000118148665,6.8907999992370605,18490,0.0,0.0,7.0058001518249515,7.729495131969452,7.855611824989319,-1.6414991877542269,-9.362771666046775,-1.6054343802818747,36.044077020840945,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-09,6.720600103903137,6.900000268820955,6.633200293521761,6.854000091552734,26237,0.0,0.0,6.972680139541626,7.682345139980316,7.850475160280864,-1.702072167571038,-9.237608926803679,-2.141654063835449,35.29284036116981,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-10,7.263400143183735,7.263400143183735,6.716000324094039,6.895400047302246,22788,0.0,0.0,6.969920110702515,7.639795124530792,7.845836822191874,-1.069166679340284,-8.768232693535989,-2.6261277455872487,36.88652643634063,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-13,6.762000165383024,6.762000165383024,6.440000241067681,6.624000072479248,58789,0.0,0.0,6.9381801128387455,7.594830131530761,7.840086821715037,-4.528277376053174,-8.646013239530692,-3.1282394667489792,31.422789437076673,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-14,6.619400233643632,6.844800130936196,6.4492002843396445,6.670000076293945,18746,0.0,0.0,6.891260099411011,7.552740120887757,7.83587015469869,-3.210733885025998,-8.758146194483317,-3.6132558123255496,33.22808617838872,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-15,6.532000183687085,6.688400260376429,6.279000085436099,6.4262003898620605,27549,0.0,0.0,6.839280128479004,7.504210126399994,7.830235159397125,-6.0398131215135455,-8.860759316716763,-4.163668476876658,28.887584142610635,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-16,6.398600220722055,6.863200347130753,6.2836002154935775,6.292800426483154,74728,0.0,0.0,6.767520189285278,7.454530143737793,7.822875161965688,-7.014678191189253,-9.216006122527258,-4.708563163819411,26.822926506417474,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-17,6.559600025230335,6.642399725910496,6.085799715155801,6.251399993896484,29212,0.0,0.0,6.674140167236328,7.406000137329102,7.8152468283971155,-6.334002024936419,-9.881986990574255,-5.236516517699663,26.19714230525139,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-20,6.095000275698575,6.476800257873533,6.01220013157237,6.325000286102295,16781,0.0,0.0,6.618020153045654,7.358620131015778,7.807771829764048,-4.427606144543236,-10.064386594010692,-5.752623264886621,29.35268067425531,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-21,6.348000200624722,6.775799909922971,6.0720000202405275,6.435400009155273,35448,0.0,0.0,6.56650013923645,7.311470115184784,7.80091016292572,-1.9964993116777914,-10.18905861902037,-6.274140292847212,33.916873634176696,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-22,6.693000087738038,6.693000087738038,6.301999912261963,6.476799964904785,14531,0.0,0.0,6.525100135803223,7.2677701115608215,7.788988490899404,-0.7402211443992227,-10.218677315841836,-6.6917338489788465,35.597184891203696,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-23,6.486000468860981,6.518200329936636,6.256000458457261,6.325000286102295,6822,0.0,0.0,6.472200155258179,7.225680112838745,7.774766826629639,-2.2743404966593146,-10.427806736721806,-7.06242034050715,32.34917037102562,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-24,6.324999962183066,6.430799750979204,6.118000051158747,6.380199909210205,36085,0.0,0.0,6.420680141448974,7.180255115032196,7.758935161431631,-0.6304664201763814,-10.57866275521348,-7.458240523467145,34.68304841564479,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-27,6.311200469185321,6.311200469185321,6.154800390411819,6.256000518798828,2167,0.0,0.0,6.383880186080932,7.1365551352500916,7.741340164343516,-2.003165215426916,-10.546754490151958,-7.812407364283694,32.00743173569549,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-28,6.256000059153465,6.306599900284157,6.1271997456914145,6.154799938201904,21012,0.0,0.0,6.332360172271729,7.088600134849548,7.722863491376241,-2.8040134995373296,-10.668396413841023,-8.212800306970923,29.9780741236858,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-29,6.301999893988763,6.890799769448234,6.127199841852789,6.578000068664551,73417,0.0,0.0,6.3475401401519775,7.052720141410828,7.711746819814047,3.6306966702703733,-9.998695356112428,-8.54575096669356,45.530791877881214,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-30,6.59180009758588,6.637800273987855,6.311200249866376,6.633200168609619,19161,0.0,0.0,6.381580114364624,7.014080131053925,7.701856819788615,3.9429114691925706,-9.017576145002815,-8.930011357359495,47.17879966643665,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-03-31,6.628600121475492,6.628600121475492,6.348000271290417,6.596400260925293,45349,0.0,0.0,6.416080141067505,6.974980127811432,7.6928484837214155,2.810440578876344,-8.012925865056122,-9.331632586148565,46.17576974045598,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-03,6.587199761228537,6.587199761228537,6.136399978533258,6.384799957275391,15231,0.0,0.0,6.422060108184814,6.933350121974945,7.681655152638753,-0.5801900057262933,-7.374357342341903,-9.741455660200467,40.8039279210798,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-04,6.256000137881956,6.458399943641995,6.163999787482664,6.3480000495910645,50359,0.0,0.0,6.413320112228393,6.898850131034851,7.670500155289968,-1.018506194830069,-7.037839778867995,-10.059970127540483,39.933835819771154,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-05,6.320400042359258,6.5320000648498535,6.246800110830389,6.5320000648498535,12102,0.0,0.0,6.418840122222901,6.868950140476227,7.660840157667796,1.7629344316456457,-6.552821159684822,-10.336856022233535,46.12032215456417,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-06,6.4307998465674245,6.440000057220459,6.24680002040863,6.440000057220459,14634,0.0,0.0,6.430340099334717,6.838820123672486,7.64995348850886,0.15022468075587145,-5.9729604953904385,-10.603114986970747,43.696950749662584,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-11,6.440000039559823,6.440000039559823,6.154800090450712,6.210000038146973,46442,0.0,0.0,6.413320112228393,6.803860116004944,7.638223489125569,-3.170277960923027,-5.7399769706885975,-10.923526580604731,38.2814270818837,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-12,6.210000038146973,6.412399846366599,6.071999949561225,6.210000038146973,49895,0.0,0.0,6.408720064163208,6.766830122470855,7.628640154997508,-3.100775568704486,-5.292139034471378,-11.297033481938227,38.2814270818837,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-13,6.182399844953748,6.403200074428983,6.071999949561225,6.210000038146973,44682,0.0,0.0,6.414240074157715,6.72876513004303,7.617945150534312,-3.1841657569632225,-4.674335480681332,-11.672176721158412,38.2814270818837,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-14,6.154800052642822,6.357199859619141,6.071999912261963,6.145599842071533,49910,0.0,0.0,6.371000051498413,6.6886301159858705,7.607058477401734,-3.537909395776372,-4.748805943511804,-12.073370595799092,36.69118082323321,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-17,6.1364001276694164,6.1364001276694164,6.035200003888234,6.108799934387207,19446,0.0,0.0,6.318560028076172,6.645735108852387,7.595443479220072,-3.3197452070868647,-4.923083382309419,-12.50365923946293,35.776605214533106,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-18,6.08120004823222,6.265199870498931,5.915599769502,6.219200134277344,21679,0.0,0.0,6.280840015411377,6.61721510887146,7.585936812559764,-0.9813954977803334,-5.083333213833682,-12.769968002955492,40.563143859577224,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-19,6.200799906297162,6.200799906297162,5.888000198711052,6.072000026702881,60672,0.0,0.0,6.249560022354126,6.586165106296539,7.57420680920283,-2.841159937917693,-5.110790247584436,-13.044820768635452,36.64185598951529,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-20,6.053600043903698,6.246800082640216,6.007600306250838,6.072000026702881,12738,0.0,0.0,6.221960020065308,6.560520100593567,7.56197847922643,-2.410172885695477,-5.160567688796922,-13.243338120889625,36.64185598951529,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-21,5.998400130059674,6.246800118624638,5.888000232628623,6.200799942016602,10355,0.0,0.0,6.188840007781982,6.5346451044082645,7.547948479652405,0.19325001485869425,-5.2918726434432175,-13.424884628926408,42.30208561318139,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-24,6.108799877166748,6.154800052642822,5.869600105285644,6.081200122833252,15191,0.0,0.0,6.152960014343262,6.507045102119446,7.535375146071116,-1.166266176648789,-5.4415649840947475,-13.646700051660114,38.832874188226775,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-25,6.062800348923398,6.164000036547437,6.062800348923398,6.099600315093994,4988,0.0,0.0,6.141920042037964,6.486460101604462,7.521460151672363,-0.689030900016857,-5.311680857811395,-13.76062664957114,39.65285229578659,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-26,6.118000087738038,6.154800052642822,5.98,6.145599842071533,37628,0.0,0.0,6.13548002243042,6.466565096378327,7.5078901489575705,0.164939329997279,-5.119952695339527,-13.86974278950826,41.754978012677384,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-27,6.145599766680479,6.384799974317383,6.090399820000465,6.219200134277344,11334,0.0,0.0,6.136400032043457,6.443565094470978,7.495355145136515,1.3493269963091696,-4.767004878884363,-14.03255790151596,45.05302315747362,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-04-28,6.256000459905257,6.384800342927895,5.980000271880829,6.292800426483154,78918,0.0,0.0,6.1511200904846195,6.427235102653503,7.483893481890361,2.3033257994378133,-4.29601543679161,-14.119099661075824,48.21107573446818,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-02,6.329600161525182,6.5135999876839765,6.2192002658299055,6.440000057220459,20210,0.0,0.0,6.184240102767944,6.412975108623504,7.47339015007019,4.135673101340964,-3.566753370802591,-14.189210253351039,53.91585626448199,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-03,6.265200093712606,6.5780002414004946,6.163999968515314,6.5320000648498535,54066,0.0,0.0,6.2155200958251955,6.396645104885101,7.462695149580638,5.091769701416129,-2.831562578351905,-14.285054170482134,57.09681074503587,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-04,6.532000029004851,6.614800170865553,6.274400270067415,6.403200149536133,4826,0.0,0.0,6.24864010810852,6.3845700979232785,7.454721816380819,2.473498853407293,-2.1290390383366975,-14.355354160983126,51.71492775102298,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-05,6.071999805125789,6.8539997035899125,6.071999805125789,6.486000061035156,26534,0.0,0.0,6.290040111541748,6.372955095767975,7.439465149243673,3.1154006336754017,-1.3010445386832847,-14.335843129584708,54.67280549186096,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-08,6.486000229770052,6.991999970791639,6.2560002278447335,6.835599899291992,54674,0.0,0.0,6.353520107269287,6.371575093269348,7.427428483963013,7.58760157965252,-0.2833677032094152,-14.215598211055394,64.54779458112482,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-09,6.798800142044991,7.166800244120149,6.55960036084477,6.854000091552734,30570,0.0,0.0,6.430800104141236,6.371575093269348,7.417691810925802,6.580829454471318,0.9295191535049256,-14.102995167790452,64.9802355451121,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-10,6.578000052269785,7.45200031077133,6.578000052269785,7.07480001449585,44036,0.0,0.0,6.528320074081421,6.376060092449189,7.409948480129242,8.370912182814843,2.3879947714505594,-13.952706829913353,69.74879771750574,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-11,7.176000431303002,7.176000431303002,6.430800018688983,6.9552001953125,57467,0.0,0.0,6.609280109405518,6.384340095520019,7.402741813659668,5.233854219837215,3.5233087604988618,-13.757088167798537,64.61625796991706,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-12,6.9000000577595495,6.946000233620689,6.486000229770052,6.835599899291992,62808,0.0,0.0,6.670920085906983,6.388480091094971,7.393426807721456,2.468622188008412,4.4210828050589095,-13.592434777023165,59.87162061129382,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-15,6.835599920259671,7.074800133567021,6.596400145642511,6.670000076293945,5913,0.0,0.0,6.708640050888062,6.394575083255768,7.384226806958517,-0.5759732867021445,4.911428258222731,-13.402238982829612,53.96320235155444,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-16,6.651600037446786,6.660799809355412,6.357199878637581,6.3755998611450195,35566,0.0,0.0,6.702200031280517,6.3966450691223145,7.374796807765961,-4.87302928308897,4.776800320423719,-13.263439849808645,45.38783682774675,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-17,6.311200028565156,6.890799686503346,6.311200028565156,6.384799957275391,9167,0.0,0.0,6.687480020523071,6.399980068206787,7.360843471686045,-4.526070542548042,4.492200745194489,-13.053713303037625,45.67835064977481,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-19,6.3848002588850274,6.854000045922251,6.1456000405870785,6.495200157165527,42444,0.0,0.0,6.696680021286011,6.404235064983368,7.3427118023236595,-3.0086529964110778,4.566430703046072,-12.78106457948279,49.17247654025325,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-22,6.495200041656068,6.67920030754154,5.924800138660508,6.56879997253418,10114,0.0,0.0,6.704960012435913,6.407570064067841,7.325538464387258,-2.0307360468845923,4.641228194066365,-12.531070648008683,51.41609778128364,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-23,6.127200135370412,6.504400450655431,6.108800152089938,6.3572001457214355,22706,0.0,0.0,6.657120037078857,6.404580068588257,7.305183466275533,-4.505249863107869,3.943115173611482,-12.32827897950712,45.23396263525292,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-24,6.347999969704803,6.5963999475385044,6.035199835140077,6.154799938201904,10430,0.0,0.0,6.587200021743774,6.400325059890747,7.285671802361806,-6.56424705663339,2.91977298190878,-12.15188889216853,40.24886826524389,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-25,6.154800127482483,6.4307998676244065,5.906400142009656,6.274400234222412,22170,0.0,0.0,6.50716004371643,6.397680068016053,7.269725139935812,-3.5769799410232768,1.711244928418684,-11.995571429918721,44.16469634232198,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-26,6.274400120223778,6.430799750784171,5.888000052355338,6.3480000495910645,35356,0.0,0.0,6.446440029144287,6.399980056285858,7.2510184725125635,-1.5270440601041253,0.7259393380889904,-11.736812138223813,46.48877861424015,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-29,6.3480002439482,6.3480002439482,6.099600255383236,6.200799942016602,13259,0.0,0.0,6.382960033416748,6.401130056381225,7.229091799259185,-2.8538497882876106,-0.2838564879081544,-11.453191713000617,42.66388709107041,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-30,6.191600134242667,6.403200155778367,5.860400005167181,6.072000026702881,32903,0.0,0.0,6.323160028457641,6.388480055332184,7.207165129979452,-3.9720646104859676,-1.022465849604127,-11.359321728897342,39.594196165451706,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-05-31,6.044400072097779,6.716000080108643,5.933999740260926,6.716000080108643,61242,0.0,0.0,6.357200050354004,6.390550053119659,7.193671794732412,5.643994634629412,-0.5218643542174342,-11.164281114421163,56.461976810993455,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-01,6.716000156191246,7.23120010206904,6.467600174452127,6.642399787902832,28415,0.0,0.0,6.382960033416748,6.391700041294098,7.180178463459015,4.0645680550690795,-0.1367399568328351,-10.981320675768709,54.5859523905707,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-02,6.440000077511993,6.99199999641784,6.210000074743707,6.338799953460693,14851,0.0,0.0,6.367320013046265,6.390550041198731,7.164231793085734,-0.4479130863084554,-0.36350592676226884,-10.799228364354299,47.56527389967234,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-05,6.311200104710797,7.212800119669482,6.118000070170352,6.642399787902832,16490,0.0,0.0,6.37467999458313,6.397910034656524,7.151045123736064,4.199736983616374,-0.36308794508770176,-10.531818441191211,53.944453332134934,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-07,6.6423998869244,6.6423998869244,6.265200022765272,6.338799953460693,22030,0.0,0.0,6.3728399753570555,6.393080031871795,7.135405123233795,-0.5341421097656691,-0.3165931978613732,-10.403404971988122,47.69549208298779,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-08,6.3296001441673,6.3296001441673,6.044400195058188,6.210000038146973,26718,0.0,0.0,6.378359985351563,6.387330031394958,7.119688451290131,-2.6395491566992573,-0.14043498612575142,-10.28638296332285,45.29809640862674,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-09,6.210000110987958,6.4400001150986235,6.090400003564766,6.403200149536133,12024,0.0,0.0,6.391239976882934,6.392160034179687,7.105581780274709,0.18713383782268306,-0.014393527255783132,-10.040300261908182,49.40615428884515,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-12,6.163999843152548,6.320399913815645,6.1271998781365475,6.311200141906738,11778,0.0,0.0,6.387559986114502,6.394690036773682,7.090785109996796,-1.195446216924099,-0.11149955069248943,-9.81689703502281,47.573971917037476,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-13,6.311200235629905,6.706800084771779,6.311200235629905,6.403200149536133,26065,0.0,0.0,6.407800006866455,6.399520039558411,7.076563449700673,-0.07178528239634482,0.1293841922028828,-9.567403937724892,49.58728992539187,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-14,6.35720014864937,6.394000115227266,6.145600121481363,6.292800426483154,12021,0.0,0.0,6.429880046844483,6.4032000541687015,7.060271787643432,-2.1319156712511522,0.41666654875809583,-9.30660678849089,47.242710070218855,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-15,6.127200138192415,6.440000292794739,6.090400171614519,6.292800426483154,11160,0.0,0.0,6.387560081481934,6.4078000664711,7.0473917881647745,-1.483503149715892,-0.3158648019477371,-9.075580596608667,47.242710070218855,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-16,6.302000198782525,6.430800081805162,6.127200138192415,6.292800426483154,16048,0.0,0.0,6.352600145339966,6.409640073776245,7.03543179432551,-0.9413424029321006,-0.8899084469601793,-8.894858749878052,47.24271007021885,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-19,6.292800063975208,6.292800063975208,6.081200048996796,6.283599853515625,21605,0.0,0.0,6.347080135345459,6.414930069446564,7.021900121370951,-1.0001493675229804,-1.0576878214817136,-8.643957353894727,47.011344745920354,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-20,6.2836002154935775,6.3296003930610505,6.164000104770311,6.292800426483154,7907,0.0,0.0,6.312120199203491,6.42045007944107,7.008713452021281,-0.3060742208739121,-1.6872630251337424,-8.393314644794875,47.28934587269141,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-21,6.256000356368277,7.028800080404449,6.154800230608824,6.596400260925293,43297,0.0,0.0,6.337880229949951,6.4303400874137875,6.997711789608002,4.078966809023838,-1.4378688561870918,-8.107960419815996,55.57235742559427,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-22,6.20999996268231,6.964400116077368,6.20999996268231,6.3480000495910645,12545,0.0,0.0,6.3516802310943605,6.437010085582733,6.985215123494466,-0.0579402830337698,-1.3256131861512765,-7.848076662204287,48.81361430376647,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-26,6.348000144141062,6.440000057220459,6.311200178909303,6.440000057220459,11558,0.0,0.0,6.355360221862793,6.445520079135894,6.972565126419068,1.331786592780376,-1.3987987961584065,-7.558840078613222,51.18176731233828,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-27,6.440000039559823,6.52280018044931,6.210000038146973,6.210000038146973,7962,0.0,0.0,6.345240211486816,6.447130084037781,6.954280122121175,-2.131364122275742,-1.5803911387367569,-7.292631719999005,45.51268870475206,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-28,6.7896001258049345,6.7896001258049345,6.283599948799644,6.311200141906738,1126,0.0,0.0,6.336040210723877,6.449430084228515,6.938065115610758,-0.39204405261028064,-1.7581378823211462,-7.042814145442455,48.22984389935187,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-29,6.550400049255711,6.605599997915203,6.210000146510417,6.467600345611572,27970,0.0,0.0,6.353520202636719,6.453800082206726,6.924878450234731,1.7955423031079731,-1.5538113714814534,-6.802695114627418,52.197303405417806,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-06-30,6.4860002913968335,6.50440027417808,6.256000287286168,6.403200149536133,28691,0.0,0.0,6.364560174942016,6.452880084514618,6.910771779219309,0.6071114661818467,-1.368689769775024,-6.625767849570312,50.48175860940896,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-03,6.660799712604213,7.166799882244169,6.486000100667685,6.614799976348877,24071,0.0,0.0,6.396760129928589,6.454950082302093,6.897815108299255,3.4085981339231775,-0.9014779608140865,-6.420366725462377,55.64060303100713,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-04,6.449200375866105,6.697600364685059,6.440000165059011,6.697600364685059,22417,0.0,0.0,6.438160181045532,6.462310087680817,6.8839384396870935,4.029725516978273,-0.373703927970307,-6.1248129352162195,57.506186458894156,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-05,6.531999874955697,6.706799926600182,6.513599892608392,6.679200172424316,11033,0.0,0.0,6.476800155639649,6.467140090465546,6.87029177347819,3.1250001840558372,0.14937151567730134,-5.868043109449228,56.93316741168568,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-06,6.614800386647442,6.614800386647442,6.210000313564835,6.421600341796875,39725,0.0,0.0,6.459320163726806,6.456790101528168,6.852620108922323,-0.5839596269240855,0.03918451984430434,-5.776330820947916,49.497117534297686,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-07,6.292800400562782,6.522800410072355,6.219200467710151,6.458400249481201,16589,0.0,0.0,6.470360183715821,6.446900105476379,6.833606779575348,-0.18484186189077198,0.363897033545056,-5.658895610657297,50.49192453285661,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-10,6.219200524600676,6.4308001141425075,5.980000301951323,6.421600341796875,33035,0.0,0.0,6.468520212173462,6.430570113658905,6.815475110212962,-0.7253570961761188,0.5901513838399595,-5.647515255059448,49.44307586850648,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-11,6.605599822918019,6.605599822918019,6.1087998594537485,6.578000068664551,15153,0.0,0.0,6.50532021522522,6.421140110492706,6.800103445847829,1.1172371387534297,1.310983770544992,-5.572905447291681,53.83244148941234,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-12,6.256000231061664,6.522800198337011,6.24680002040863,6.440000057220459,2899,0.0,0.0,6.518200206756592,6.411250114440918,6.784156775474548,-1.1997199695565113,1.6681628451021686,-5.496728235728978,49.729781896372465,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-13,6.007600353388326,6.430799961090088,6.007600353388326,6.430799961090088,2577,0.0,0.0,6.514520168304443,6.405270111560822,6.768018440405528,-1.2851323666428316,1.7056276291367805,-5.359742028465435,49.459158056264585,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-14,6.348000144141062,6.587199918147494,6.090399948828559,6.440000057220459,32671,0.0,0.0,6.518200159072876,6.406880116462707,6.752685109774272,-1.199719246785755,1.7375078132666786,-5.120999834732769,49.75362659596337,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-17,6.274400249923641,6.522800236018071,6.1548001428844215,6.504400253295898,31688,0.0,0.0,6.507160186767578,6.40987012386322,6.73861677646637,-0.0424137933055968,1.5178164459550965,-4.878547979627649,51.86766498217517,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-18,6.25600049136362,6.495200275322766,6.154800363420417,6.421600341796875,15181,0.0,0.0,6.47956018447876,6.4080301284790036,6.723628441492717,-0.8945027290698296,1.1162565494481258,-4.693869028605142,49.01243066576639,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-19,6.2468000986161085,6.366400206461766,6.108800007924211,6.237600326538086,23670,0.0,0.0,6.435400199890137,6.399750137329102,6.706263438860575,-3.0736219536964886,0.5570539754840073,-4.570552653141097,43.30714631284059,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-20,6.154800204098762,6.43079994767639,5.998400130059674,6.200799942016602,30382,0.0,0.0,6.413320159912109,6.395840132236481,6.689396770795186,-3.3137316178897875,0.273303073782671,-4.388387303326445,42.24790380645273,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-21,6.4399999616888355,6.4399999616888355,6.163999787854669,6.412399768829346,12586,0.0,0.0,6.4087201118469235,6.402280128002166,6.676095100243886,0.05741640948900471,0.10058891076305777,-4.101424082945089,49.844241612200676,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-24,6.3939998245239265,6.3939998245239265,6.035199947357178,6.145599842071533,38781,0.0,0.0,6.381120061874389,6.399060118198395,6.658998433748881,-3.6908915287463566,-0.2803545519596742,-3.903564749813978,42.29090886274035,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-25,6.072000042231731,6.329600240769286,6.0260003044612285,6.237600326538086,13828,0.0,0.0,6.347080087661743,6.39630012512207,6.6442784388860066,-1.7248838774931718,-0.7695079420524844,-3.7322083360117726,45.365448515075876,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-26,6.237600311845952,6.338799997916807,5.888000199900651,6.0076003074646,37239,0.0,0.0,6.303840112686157,6.39147013425827,6.627066775163015,-4.699354677879445,-1.371046406090769,-3.5550666516250584,39.674670631551976,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-27,6.301999812981278,6.301999812981278,5.869600012816917,6.053599834442139,17228,0.0,0.0,6.266120100021363,6.391010129451752,6.610736775398254,-3.391576640519537,-1.9541516427091472,-3.3237845252621643,41.26167513811085,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-28,6.0536002520996295,6.200800119555604,5.9616003349396465,6.090400218963623,22355,0.0,0.0,6.231160116195679,6.375370132923126,6.593333439032237,-2.258967746089539,-2.2619865783592776,-3.3058134875869873,42.563492785295445,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-07-31,6.09040011494658,6.338800106381253,5.9984001993578495,6.3296003341674805,26606,0.0,0.0,6.213680124282837,6.367550146579743,6.57807677189509,1.865564489417985,-2.4164713077219435,-3.200428219610102,50.27742657061728,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-01,6.348000425701786,6.348000425701786,5.980000318371643,6.090400218963623,15125,0.0,0.0,6.180560111999512,6.3613401532173155,6.561746772130331,-1.4587657332357937,-2.841854654264516,-3.0541656950890124,43.924428958229356,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-02,5.980000112706966,6.375599962234496,5.869600215911869,6.072000026702881,17536,0.0,0.0,6.164000082015991,6.347080159187317,6.547946774959565,-1.4925381909310542,-2.8844771545278127,-3.067627497223941,43.469404229401114,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-03,6.0720000480393255,6.38480019541478,5.860400025760082,5.970799922943115,70307,0.0,0.0,6.141000080108642,6.337880158424378,6.5333034435908,-2.7715381036522655,-3.106402667681248,-2.9911864166990907,40.95639611830122,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-04,5.8971997832059895,6.026000097393989,5.694799978852273,5.888000011444092,49180,0.0,0.0,6.088560104370117,6.329830157756805,6.518660104274749,-3.2940480095133102,-3.811635500061987,-2.8967601239726384,38.9712688867144,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-07,5.878799973134918,5.888000183856396,5.750000093865584,5.8420000076293945,17327,0.0,0.0,6.058200120925903,6.315800154209137,6.50394010146459,-3.5687185794626064,-4.078660296297652,-2.8927072562228253,37.872999218192156,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-08,5.841999854495681,6.044400098160831,5.749999943143423,5.786799907684326,16788,0.0,0.0,6.013120079040528,6.302690148353577,6.4880701025327046,-3.7637726900726367,-4.594388467418028,-2.8572433905540318,36.54216074731617,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-09,5.7868000004521125,6.210000038146973,5.7868000004521125,6.210000038146973,24856,0.0,0.0,6.0333600521087645,6.297860145568848,6.47538177172343,2.92772160972673,-4.199840697418225,-2.7414850955935903,50.81267094709566,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-10,6.210000282337784,6.808000397263909,5.7960004389913475,6.292800426483154,77685,0.0,0.0,6.057280111312866,6.297860145568848,6.46323010524114,3.8882189834744354,-3.8200282110940953,-2.5586271412213955,53.03789154490547,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-11,6.430799711347501,6.430799711347501,6.191599942370703,6.283599853515625,6012,0.0,0.0,6.076600074768066,6.297630131244659,6.450388435522715,3.4065065365595815,-3.5097338501984843,-2.368203183498307,52.752311073939325,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-14,6.256000156374497,6.283599910623722,6.1180000690578185,6.246799945831299,12719,0.0,0.0,6.068320035934448,6.296480119228363,6.441111767292023,2.9411749683595394,-3.623613177101176,-2.2454454027346613,51.55655476379636,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-15,6.035200040592699,6.200799885222521,6.035200040592699,6.1732001304626465,6805,0.0,0.0,6.076600027084351,6.293720126152039,6.431605100631714,1.5897064632810134,-3.4497895476079012,-2.1438656808411976,49.15662818675018,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-16,6.173200073016131,6.283599968408655,6.071999949561225,6.210000038146973,6088,0.0,0.0,6.09040002822876,6.291650116443634,6.424206765492757,1.9637463773130144,-3.1986853129180584,-2.063393254419256,50.399858721531345,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-17,6.163999899475452,6.283600006215381,5.878799948650368,6.274400234222412,28799,0.0,0.0,6.120760059356689,6.283600115776062,6.416195102532705,2.5101486314735735,-2.5915089028427385,-2.066567251115894,52.58489756063987,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-18,5.98920053284041,6.219200545216336,5.842000226610476,6.026000499725342,32230,0.0,0.0,6.1345601081848145,6.275550127029419,6.406535104910533,-1.7696396570412756,-2.246655926423828,-2.044552566030821,44.450878005081115,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-21,6.007600541144432,6.1640001817075225,5.888000428928353,5.924800395965576,30562,0.0,0.0,6.142840147018433,6.2626701354980465,6.398216772079468,-3.5494941400792763,-1.9134009278309894,-2.1185064746933766,41.62585577902409,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-22,6.136400185845118,6.136400185845118,5.823600039568815,6.072000026702881,8516,0.0,0.0,6.171360158920288,6.259220135211945,6.390971771876017,-1.610019990063117,-1.4036888684804385,-2.0615274385009132,46.910996386859075,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-23,6.154800169887803,6.154800169887803,5.85120023429485,6.0076003074646,3751,0.0,0.0,6.151120185852051,6.251630139350891,6.381541772683462,-2.333231574917941,-1.6077399215635058,-2.035740546095994,44.99174953326153,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-24,6.127199938275125,6.127199938275125,5.796000249880388,5.94320011138916,13376,0.0,0.0,6.116160154342651,6.238520133495331,6.3731851061185205,-2.82791880181039,-1.9613622547391407,-2.1129932738640522,43.09307065006142,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-25,5.943199958086015,6.062800061821937,5.83280006480217,5.888000011444092,18218,0.0,0.0,6.076600170135498,6.22564013004303,6.363831774393717,-3.103711835745159,-2.3939700463621585,-2.1715163010237326,41.47734741266414,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-28,6.4123997238874475,6.6147999669313435,5.694799978852273,5.888000011444092,9627,0.0,0.0,6.0407201766967775,6.20747013092041,6.353021772702535,-2.528178110978103,-2.686278801294981,-2.291061592257188,41.47734741266414,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-29,5.713200277966275,5.869600354805352,5.713200277966275,5.832800388336182,5642,0.0,0.0,6.006680202484131,6.185850131511688,6.3442434390385944,-2.8947739564366923,-2.8964479452038026,-2.496646117837327,39.74892254621206,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-30,5.713200335911335,5.84200021985976,5.630400191170814,5.7960004806518555,12399,0.0,0.0,5.965280246734619,6.163770139217377,6.334621775150299,-2.837750433861464,-3.2202675959613245,-2.6971087145746515,38.59425362113131,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-08-31,5.961599977548839,5.961599977548839,5.529200173473664,5.6855998039245605,17120,0.0,0.0,5.906400203704834,6.145370125770569,6.324578440189361,-3.7383243966735398,-3.888617238262283,-2.8335218878782187,35.28289638351164,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-01,5.639600124328068,5.703999843783798,5.547600211755461,5.648799896240234,23208,0.0,0.0,5.868680143356324,6.125130116939545,6.314535105228424,-3.746672876098147,-4.186849400537432,-2.9995080418834434,34.22867185992031,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-04,5.529200342984096,5.612000046657649,5.464800183513379,5.575200080871582,23294,0.0,0.0,5.833720111846924,6.103970110416412,6.303533438841502,-4.431478130915954,-4.427446296113199,-3.165896244722169,32.159068928147676,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-05,5.612000046657649,5.740799926908886,5.382000041149629,5.575200080871582,30288,0.0,0.0,5.784040117263794,6.078900110721588,6.294793438911438,-3.610625655394078,-4.850548423023734,-3.4297126710353885,32.159068928147676,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-06,5.9432000145594275,5.9432000145594275,5.437199840831757,5.519999980926514,11954,0.0,0.0,5.735280084609985,6.05590010881424,6.285210104783376,-3.753610992097017,-5.294341360380079,-3.6484062130973043,30.552229792542207,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-07,5.510799674604407,5.519999884983998,5.381999800121363,5.4923996925354,15407,0.0,0.0,5.6902000427246096,6.032440102100372,6.277428432305654,-3.476158108748975,-5.673327104509524,-3.902686153210345,29.751768816389358,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-08,5.4923996925354,5.4923996925354,5.381999800121363,5.4923996925354,11456,0.0,0.0,5.65064001083374,6.008750092983246,6.270758426189422,-2.8003963797897615,-5.959809887378924,-4.178255888664363,29.751768816389358,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-11,5.262399862925211,5.4555999000744935,5.234800108298279,5.381999969482422,27598,0.0,0.0,5.600040006637573,5.980690085887909,6.263513425985972,-3.8935442764107817,-6.364651466367094,-4.515410455171849,26.527592254289132,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-12,5.225599975117466,5.280799923880057,5.142800271318678,5.24399995803833,27063,0.0,0.0,5.541159963607788,5.951250076293945,6.254505089918772,-5.36277616096793,-6.890823061186755,-4.848585287965047,23.150369037508156,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-13,5.152000100974903,5.2256000334803705,5.00480023596397,5.207200050354004,50480,0.0,0.0,5.482279920578003,5.925490069389343,6.244270090262095,-5.017618111608526,-7.479721400613455,-5.105160671539297,22.333829136023127,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-14,5.234800185922996,5.317600328411982,5.152000043434011,5.24399995803833,8371,0.0,0.0,5.43811993598938,5.901570069789886,6.233996756871542,-3.569615606790264,-7.852997224804733,-5.3324809114671385,25.175967941777515,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-15,5.372800028431948,5.841999790536696,5.299200100155923,5.4923996925354,49989,0.0,0.0,5.422479915618896,5.878570067882538,6.227058418591818,1.2894428011638612,-7.758522004449377,-5.596355892034282,40.89788482250509,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-18,5.492399902025328,5.952399909985882,5.372800233360131,5.510799884796143,11622,0.0,0.0,5.416039896011353,5.862700068950653,6.219813418388367,1.7496176284553577,-7.618676850020865,-5.74154440681351,41.8722104230165,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-19,5.786800300230886,5.970800135416998,5.455600158205672,5.924800395965576,21805,0.0,0.0,5.450999927520752,5.85488007068634,6.217053417364756,8.691991831677019,-6.898179608967514,-5.825482304315341,58.46388341385111,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-20,5.970799969119409,5.970799969119409,5.520000166123918,5.703999996185303,19743,0.0,0.0,5.469399929046631,5.847290062904358,6.213296751181285,4.28932003843363,-6.4626541490577045,-5.890700266446161,50.22920999265555,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-21,5.464799977612021,5.6396000278548675,5.428000013212493,5.55679988861084,4053,0.0,0.0,5.4758399486541744,5.834870064258576,6.204786749680837,1.4784935410057656,-6.153180990329774,-5.961795309746768,45.61633133685593,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-22,5.556800275218201,5.584400469783185,5.372800440419006,5.4648003578186035,8664,0.0,0.0,5.473080015182495,5.81923006772995,6.195050084590912,-0.15127966959962613,-5.948382320661302,-6.066456472979097,42.96080702259297,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-25,5.428000263267005,5.428000263267005,5.207200028007939,5.3084001541137695,36311,0.0,0.0,5.4657200336456295,5.7937000632286075,6.184316750367483,-2.878301094154795,-5.660977026832958,-6.31624644898184,38.82312766161858,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-26,5.409600256078392,5.473999977111816,5.225599987735268,5.473999977111816,22589,0.0,0.0,5.488720035552978,5.778290057182312,6.176726750532786,-0.26818745255384,-5.011344511330022,-6.450612265082073,44.87688980175349,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-27,5.473999824523926,5.473999824523926,5.326799964904786,5.418799877166748,4901,0.0,0.0,5.509880018234253,5.761960053443909,6.168983415762583,-1.6530331108134264,-4.374900778060555,-6.59790008964321,43.33743834468335,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-28,5.262399953665853,5.473999977111816,5.207200004769975,5.473999977111816,20348,0.0,0.0,5.532880020141602,5.749540054798127,6.160166748364767,-1.0641843455025513,-3.7683020309723196,-6.665837311557228,45.35612728178149,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-09-29,5.2164003281211615,5.455600111829765,5.2164003281211615,5.400400161743164,12892,0.0,0.0,5.523680067062378,5.737350058555603,6.1515034159024555,-2.231843695190273,-3.724193038815863,-6.732555106386038,43.148815793345264,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-02,5.4004000693507965,5.428000263267005,5.069200374497498,5.3084001541137695,69023,0.0,0.0,5.503440093994141,5.724010062217713,6.143990083535512,-3.5439640760915476,-3.853416849831918,-6.835623358886112,40.49583653307544,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-03,5.1060002501553345,5.372800218962278,5.0968000394494855,5.216400146484375,22010,0.0,0.0,5.43260006904602,5.709750068187714,6.135710084438324,-3.9796767627625247,-4.8539777719143045,-6.94231002424561,37.98096583066209,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-04,5.2164000891303015,5.271600036687901,5.1519999309680085,5.253200054168701,5383,0.0,0.0,5.38752007484436,5.685830068588257,6.127736751238505,-2.4931697480410695,-5.246551341587394,-7.211580728577023,39.59684346725928,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-05,5.243999863843587,5.243999863843587,5.013999862119041,5.087600231170654,15083,0.0,0.0,5.340600109100341,5.655700063705444,6.118920087814331,-4.737293052490061,-5.57136961040785,-7.5702904672897695,35.157676683424924,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-06,5.087600322556087,5.280799923880057,5.087600322556087,5.24399995803833,12049,0.0,0.0,5.3185200691223145,5.629710066318512,6.111713421344757,-1.4011437414070342,-5.527638076035,-7.886550330434022,41.794575022432106,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-09,4.986400242169117,5.078400157604116,4.885200115845519,4.977200031280518,22352,0.0,0.0,5.28540005683899,5.597970068454742,6.10136342048645,-5.831157949144829,-5.5836313483904405,-8.250505949891004,35.1795527475972,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-10,4.885199983986547,5.1060002137610105,4.885199983986547,5.087600231170654,14294,0.0,0.0,5.246760082244873,5.570830070972443,6.093160088857015,-3.0334882590271017,-5.81726573237586,-8.572399383364198,39.450193077917596,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-11,5.087600135491109,5.18879981848977,4.949600049313631,5.059999942779541,11970,0.0,0.0,5.210880088806152,5.542080068588257,6.08472675482432,-2.8954829789832837,-5.976095178763307,-8.918176741557403,38.76261427899959,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-12,5.234800014893905,5.289999961853027,4.931200087273639,5.289999961853027,8727,0.0,0.0,5.192480087280273,5.517470061779022,6.077136754989624,1.8780981907209016,-5.890199146707483,-9.209381255919382,47.045392497974944,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-13,5.244000104315128,5.244000104315128,4.922000174873008,5.004800319671631,31168,0.0,0.0,5.15292010307312,5.491940057277679,6.068166756629944,-2.8744824378928873,-6.173045420539594,-9.495894270253741,39.84804884549518,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-16,2.7600000951911543,2.907200179232252,2.254000121608463,2.488600015640259,1003574,0.0,0.0,4.870940089225769,5.406035047769547,6.0380750874678295,-48.90924605817069,-9.898103763950813,-10.467575022544803,16.240842069496935,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-17,2.4840000046321316,2.4840000046321316,2.143599895949592,2.4149999618530273,309123,0.0,0.0,4.590800070762635,5.3146100461483,6.006986755132675,-47.394791220959405,-13.619248996645355,-11.526190038504293,15.943310097454543,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-18,2.3735999771264886,2.658800149514129,2.258599974834002,2.3919999599456787,107109,0.0,0.0,4.304680061340332,5.224220037460327,5.975093420346578,-44.43257278449422,-17.601478680576687,-12.566722058760673,15.845615927707158,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-19,2.3919999599456787,2.47939998800938,2.2724000716209436,2.3919999599456787,72826,0.0,0.0,4.035120034217835,5.13544003367424,5.942586749792099,-40.72047573153936,-21.426012030933254,-13.582413687879216,15.845615927707158,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-20,2.300000009691812,2.424200001441366,2.2540000533669944,2.263200044631958,20471,0.0,0.0,3.7370400428771973,5.044820034503937,5.907780083020528,-39.43869964825183,-25.923223874830164,-14.607179623981144,15.239147901221202,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-23,2.263200073010996,2.286199941789261,2.166600053845032,2.2769999504089355,31657,0.0,0.0,3.467020034790039,4.954545032978058,5.872321748733521,-34.324003681541186,-30.023442885004993,-15.628856098584839,15.611818934384246,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-24,2.309200022246358,2.309200022246358,2.065399922459479,2.1298000812530518,35918,0.0,0.0,3.1712400197982786,4.861970025300979,5.836710081497828,-32.84014871291491,-34.774587187999714,-16.70016229325389,14.861231797112879,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-25,2.2080000781613913,2.2080000781613913,2.0056000527178393,2.1988000869750977,69946,0.0,0.0,2.8851200342178345,4.77204001545906,5.800983415047328,-23.788263195392506,-39.54116007260069,-17.737395989088043,16.878607601616423,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-26,2.1988001914819084,2.2494000357389385,2.0240001312891627,2.2080001831054688,63485,0.0,0.0,2.5769200563430785,4.685100024938583,5.762420084079107,-14.316310369408432,-44.99754450009081,-18.695618219800274,17.16046214157734,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-27,2.2080000502931534,2.378199994763956,2.1206000254539363,2.2493999004364014,28865,0.0,0.0,2.3013800144195558,4.600115025043488,5.724048415819804,-2.2586497517779387,-49.9712506776328,-19.63528798376429,18.499710341132484,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-30,2.267800062935598,2.295400038341161,2.125200080334303,2.2862000465393066,59923,0.0,0.0,2.2811400175094603,4.5178900241851805,5.684143416086832,0.22182018600378986,-49.50873072832548,-20.517663023790174,19.741790771958478,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-10-31,2.286199977983421,2.346000032574813,2.1482001050937845,2.341400146484375,16062,0.0,0.0,2.273780035972595,4.4370450258255,5.645695082346598,2.9739073015853923,-48.75463235693525,-21.408348111119203,21.670171347656478,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-01,2.484000107899017,2.829000116792072,2.2080001446535924,2.5898001194000244,27245,0.0,0.0,2.2935600519180297,4.363790029287339,5.610313417514165,12.916167912597656,-47.44109967425273,-22.218426948046336,29.83960031358403,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-02,2.5759999561309814,2.5759999561309814,2.313800096511841,2.313800096511841,92952,0.0,0.0,2.285740065574646,4.284325039386749,5.5740117510159815,1.2276125076427085,-46.64877093681429,-23.137495384615217,26.5288582891246,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-03,2.3184000462960923,2.553000158042114,2.3184000462960923,2.4242000579833984,43033,0.0,0.0,2.30184006690979,4.20762004852295,5.541083419322968,5.31574685976668,-45.29353790588026,-24.065029704298265,29.880191043343757,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-06,2.424200040211221,2.9118000237425847,2.3276000207116483,2.359800100326538,60002,0.0,0.0,2.3101200819015504,4.1320650517940525,5.507541753848394,2.1505383557418423,-44.09284333753297,-24.9744216844698,29.047822446285764,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-07,2.4840000534948903,2.4840000534948903,2.327599982698387,2.4609999656677246,63009,0.0,0.0,2.3432400703430174,4.062490051984787,5.473923418919245,5.025515601884907,-42.32010317912792,-25.784675066081352,32.24209045670736,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-08,2.4425999188337086,2.5897999944927874,2.3919998585532305,2.5483999252319336,9777,0.0,0.0,2.378200054168701,3.9960200488567352,5.440420085191727,7.156667529499562,-40.485782726512944,-26.54942106890794,34.96521384657177,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-09,2.5484000013215202,2.66800010749272,2.405800026587078,2.5759999752044678,123561,0.0,0.0,2.4150000333786013,3.929320049285889,5.408910083770752,6.666664165657445,-38.53898376596986,-27.354679807385256,35.842095159239975,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-10,2.759999989727027,2.759999989727027,2.2999999914391895,2.5622000694274902,306124,0.0,0.0,2.44628005027771,3.856065058708191,5.378971751530965,4.738624228105888,-36.56019768771145,-28.312227004897807,35.58375152340227,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-13,2.3551999292391352,2.4840000247601446,2.3506000433339693,2.4793999195098877,28140,0.0,0.0,2.465600037574768,3.7802800595760346,5.347346748908361,0.5596966955229957,-34.77731811617974,-29.305499772428945,34.00022321191143,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-14,2.4840000046321316,2.502399986793881,2.2999999636695496,2.4149999618530273,137103,0.0,0.0,2.472960019111633,3.692535048723221,5.314571748177211,-2.343752297274381,-33.02812332230357,-30.520553231976127,32.77842001431161,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-15,2.415000157621169,2.5484001487802534,2.3920000683819724,2.4840002059936523,30529,0.0,0.0,2.462380027770996,3.6120350539684294,5.283598417043686,0.8780195574534143,-31.82845706146576,-31.636835942776685,35.45471358298114,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-16,2.484000101302193,2.484000101302193,2.36900009864325,2.4748001098632812,27114,0.0,0.0,2.47848002910614,3.5349850594997405,5.253621751070023,-0.14847483940332035,-29.88711444633697,-32.71336942405954,35.25317892580048,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-17,2.566800002446249,2.612799959250016,2.442600009403531,2.6082000732421875,54171,0.0,0.0,2.496880030632019,3.46357005238533,5.219390084346135,4.458365690160558,-27.910220008039392,-33.64032968577721,40.53166709002013,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-20,2.608200203147632,2.760000177833243,2.4472002366430474,2.516200065612793,126771,0.0,0.0,2.5125200271606447,3.3937650501728056,5.185005086660385,0.14646802462733033,-25.96658902381263,-34.546543475838725,38.217623097136475,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-21,2.4840002059936523,2.5162000677143994,2.4840002059936523,2.4840002059936523,16392,0.0,0.0,2.5148200511932375,3.3190150558948517,5.152881755431493,-1.225528847877671,-24.22992939647248,-35.58914771532685,37.41253196409401,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-22,2.479399879043166,2.479399879043166,2.3551998907995033,2.3827998638153076,28744,0.0,0.0,2.4982600450515746,3.2431150555610655,5.11738508939743,-4.621623816342282,-22.967270594740878,-36.625542168394034,34.92252964753371,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-23,2.382799871635439,2.428800046157835,2.2953998471260095,2.299999952316284,83145,0.0,0.0,2.4706600427627565,3.1637650549411775,5.083728422721227,-6.9074695624913165,-21.90760060061753,-37.766835836449495,32.98801758256033,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-24,2.424200021023807,2.424200021023807,2.263200062913858,2.3276000022888184,32377,0.0,0.0,2.4472000360488892,3.0869450509548186,5.051375089089076,-4.887219352659472,-20.724211294530516,-38.889015436161294,34.294584309773896,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-27,2.327600077353419,2.3782001410238482,2.28160011917353,2.3552000522613525,16252,0.0,0.0,2.4347800493240355,3.0131150484085083,5.017641754945119,-3.268467600791152,-19.19392355728144,-39.94957799769297,35.64584884344205,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-28,2.3414001881062765,2.3414001881062765,2.212600085107901,2.272400140762329,27693,0.0,0.0,2.420520067214966,2.939515048265457,4.983985088268915,-6.119343047755126,-17.65580282899857,-41.02078966519466,33.425017674820396,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-29,2.254000186920166,2.3092001377806337,2.1298001878115604,2.254000186920166,50001,0.0,0.0,2.397520065307617,2.8645350515842436,4.949408421913783,-5.9861804897568875,-16.303343400121488,-42.12368817854364,32.933971611148124,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-11-30,2.20800007829961,2.254000034233958,2.1251999382726923,2.2309999465942383,14766,0.0,0.0,2.373140048980713,2.793120044469833,4.915560084581375,-5.989537045971027,-15.036231483163382,-43.177989966372174,32.29528179630705,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-01,2.1619998750647103,2.2769998730861327,2.1343999018609794,2.2172000408172607,35594,0.0,0.0,2.33404004573822,2.7174500465393066,4.881596748034159,-5.005912607810669,-14.109183029486113,-44.33276268397967,31.895608432803115,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-04,2.2080000795196586,2.5622000694274902,2.1527999130228483,2.5622000694274902,32687,0.0,0.0,2.33864004611969,2.657075047492981,4.850508411725362,9.559402853754026,-11.98441879440863,-45.220689833875795,48.91626954947123,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-05,2.562200227402401,2.562200227402401,2.2172002074152157,2.304600238800049,179516,0.0,0.0,2.3207000494003296,2.587500047683716,4.817350081602732,-0.6937480181655085,-10.31111085475036,-46.287896792776685,40.73092906565053,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-06,2.2677999120115553,2.4564000604157252,2.22640006133096,2.3966000080108643,71194,0.0,0.0,2.322080063819885,2.5209150493144987,4.78488174478213,3.2091892675049216,-7.887413165655143,-47.314997866696835,44.314774343060414,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-07,2.396600171913219,2.396600171913219,2.2954000425616417,2.369000196456909,46229,0.0,0.0,2.3289800882339478,2.447890055179596,4.74965341091156,1.7183533867525869,-4.857651457590656,-48.461711973426006,43.46564984339973,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-08,2.3966000080108643,2.3966000080108643,2.2724000172788945,2.3966000080108643,29352,0.0,0.0,2.335880088806152,2.382685047388077,4.716725077231725,2.5994450441052184,-1.9643787429325943,-49.48433482185293,44.60865818187993,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-11,2.3966001257754757,2.3966001257754757,2.2862000067304775,2.323000192642212,39628,0.0,0.0,2.332660102844238,2.3785450518131257,4.682416745026907,-0.41411563520325323,-1.929118346272658,-49.20261947338782,42.16072075499073,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-12,2.3230000614686435,2.5759999270005665,2.2724000006242226,2.5299999713897705,59971,0.0,0.0,2.3584200859069826,2.3814200520515443,4.651750077803929,7.275204553594322,-0.9658088720949368,-48.805932988218444,50.404091656489285,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-13,2.5484000925222983,2.5484000925222983,1.8400000794728566,2.2080001831054688,499088,0.0,0.0,2.3538200855255127,2.376820057630539,4.617556744813919,-6.195031783301665,-0.9676783074590429,-48.526456977491435,40.68931653939548,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-14,2.3138001649005884,2.4472001512958705,2.208000152999665,2.2585999965667725,118163,0.0,0.0,2.3565800905227663,2.3734850585460663,4.582481741905212,-4.15772391314138,-0.7122424454466768,-48.20524789348607,42.56275141147797,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-15,2.4656000013967314,2.4656000013967314,2.221799910819696,2.350600004196167,227723,0.0,0.0,2.369920086860657,2.3756700575351717,4.54871007402738,-0.8152208494963432,-0.2420357429802578,-47.77266480227045,45.9082462523848,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-18,2.35060010827505,2.4426000223710003,2.35060010827505,2.3919999599456787,10732,0.0,0.0,2.3529000759124754,2.3785450577735903,4.513520073890686,1.6617740988443812,-1.0781793591549427,-47.30177292147795,47.39317470076714,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-19,2.5760000516690127,2.5760000516690127,2.387400114864696,2.5714001655578613,44246,0.0,0.0,2.3795800685882567,2.3895850598812105,4.479135072231292,8.06109025292881,-0.418691573735032,-46.65074793802026,53.36728101011157,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-20,2.4472000983289193,2.8519999348298284,2.345999974694871,2.410399913787842,298351,0.0,0.0,2.3809600591659548,2.394875055551529,4.443561736742655,1.2364699066896463,-0.5810322485642029,-46.104607127455196,48.08930233377042,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-21,2.755400024054176,2.755400024054176,2.346000066253368,2.438000202178955,128124,0.0,0.0,2.387860059738159,2.400625056028366,4.4103650689125065,2.099794007455111,-0.5317363600014081,-45.56856363320725,49.02011683087041,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-22,2.3920000118060663,2.7370000261633893,2.3920000118060663,2.5208001136779785,7855,0.0,0.0,2.400280070304871,2.4074100613594056,4.377551734447479,5.021082533831142,-0.29616853268897164,-45.005560016225346,51.81168932528644,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-27,2.438000202178955,2.723200162923558,2.382800032885562,2.438000202178955,84783,0.0,0.0,2.411780071258545,2.411205065250397,4.34435506661733,1.087169233748891,0.02384724619382303,-44.49797430743046,48.926471201095204,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-28,2.4426001040023886,2.5576001101381607,2.4426001040023886,2.5024001598358154,12902,0.0,0.0,2.4090200901031493,2.4152300655841827,4.310391734043757,3.876267786902008,-0.2571173475157688,-43.96727224329666,51.20255563721272,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2023-12-29,2.557600032813485,2.557600032813485,2.456400126985458,2.4748001098632812,27832,0.0,0.0,2.4357000827789306,2.412355065345764,4.277348401149114,1.6052890649714477,0.9677272541063668,-43.60162326974154,50.17062388612596,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-02,2.4840001185044014,2.621999991043752,2.447200152493908,2.5392000675201416,53002,0.0,0.0,2.4637600898742678,2.4179900646209718,4.244918402036031,3.0619855381180296,1.8928955053614165,-43.038008375821605,52.57249664906418,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-03,2.5391999427521412,2.7139999920579805,2.493199987499312,2.497799873352051,34493,0.0,0.0,2.478480076789856,2.419830060005188,4.212066733837128,0.779501789952569,2.4237246141384916,-42.55005409658455,50.874767275331244,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-04,2.497799949333316,2.681799995286869,2.460999984011625,2.525399923324585,36681,0.0,0.0,2.4918200731277467,2.4239700555801393,4.178908397754033,1.3476033265390897,2.799127711640336,-41.99513784789087,51.98791449385577,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-05,2.5759999752044678,2.5759999752044678,2.465600079672678,2.5759999752044678,52840,0.0,0.0,2.492280054092407,2.426845055818558,4.14686172803243,3.3591698884156225,2.6962989712492527,-41.47755061584781,54.043885856743515,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-08,2.516199858439814,2.668000039971964,2.479399894193871,2.6633999347686768,93993,0.0,0.0,2.5175800561904906,2.4297200560569765,4.117076724767685,5.792065210384427,3.6160544468689126,-40.98433868282893,57.43443356970701,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-09,2.520799955626666,2.8059998969708477,2.5161998504380074,2.7139999866485596,99961,0.0,0.0,2.5451800346374513,2.4331700563430787,4.088020058472951,6.632927718810894,4.603458685609403,-40.48047657447231,59.306313589385326,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-10,2.5622000789642336,2.709399938583374,2.5483999824523926,2.709399938583374,20384,0.0,0.0,2.564040017127991,2.436850053071976,4.057161726554235,5.669175226765858,5.219441544861368,-39.93707381387522,59.052069535334695,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-11,2.6633999148782297,2.7093998698421284,2.534600040979314,2.631199836730957,35809,0.0,0.0,2.583359980583191,2.4406450510025026,4.027875059843064,1.85184629735444,5.847426667883051,-39.40613810653808,54.754716414813466,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-12,2.668000097425097,2.7553999047187494,2.6266000270843506,2.6266000270843506,25389,0.0,0.0,2.5957799673080446,2.4459350526332857,3.997783390680949,1.1873140314072128,6.126283464208764,-38.81771938082254,54.503465725192456,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-15,2.603599891796918,2.66800004878514,2.5990000059235245,2.612799882888794,13796,0.0,0.0,2.6095799446105956,2.4491550445556642,3.9694933871428173,0.12338914103199906,6.55021414065014,-38.3005636817919,53.707220477623814,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-16,2.7600001668521124,2.7600001668521124,2.6128000789890953,2.681800127029419,88183,0.0,0.0,2.6238399505615235,2.4543300449848173,3.9413950562477114,2.2089829242630237,6.906565232458571,-37.729407736117935,57.083214049567054,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-17,2.5852000751852784,2.7416001531090846,2.5852000751852784,2.700200080871582,3352,0.0,0.0,2.6440799713134764,2.4566300451755523,3.9131433884302775,2.1224815499898573,7.630368541085267,-37.22105731062905,57.963583233225194,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-18,2.6956002119494626,2.8934001440311494,2.6082001807472928,2.7324001789093018,63232,0.0,0.0,2.6647799968719483,2.462035048007965,3.883166720469793,2.5375521475217226,8.234852262888156,-36.597235575038525,59.528225411576955,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-19,2.713999989939194,2.888800039108569,2.5851998959867366,2.8796000480651855,97565,0.0,0.0,2.69514000415802,2.4719250440597533,3.856410052378972,6.844172978865047,9.030005203218895,-35.90087645024022,65.7958510281793,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-22,2.870399982085231,2.870399982085231,2.6450000805100244,2.8198001384735107,53531,0.0,0.0,2.7107800245285034,2.4828500509262086,3.8293083866437274,4.021724852571526,9.180174755912757,-35.16191958876544,61.620852844346835,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-23,2.898000038891303,2.898000038891303,2.686400024910283,2.8289999961853027,27327,0.0,0.0,2.7222800254821777,2.496075052022934,3.8031267205874126,3.9202422125630685,9.062426759801035,-34.36781797169772,62.02013187374266,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-24,2.8290000827751345,2.884200030891455,2.7461999412555573,2.7738001346588135,15057,0.0,0.0,2.7287200450897218,2.507230055332184,3.777175054947535,1.6520598971012965,8.834051318365855,-33.621555293073136,58.11352287650917,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-25,2.755399828179312,2.833599861386219,2.6955999963255777,2.7646000385284424,70344,0.0,0.0,2.74206006526947,2.517465054988861,3.7515300552050275,0.8220087351280212,8.9214747920941,-32.89497837033116,57.46384067334982,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-26,2.7646002169398587,2.8336000442504883,2.6818000732149407,2.8336000442504883,38168,0.0,0.0,2.762760066986084,2.531495052576065,3.7269200563430784,2.5641016790026305,9.135511214003058,-32.07541309431752,60.98657053023956,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-29,2.6956000980627355,2.805999994277954,2.6956000980627355,2.805999994277954,7381,0.0,0.0,2.782080078125,2.5452950477600096,3.698553389310837,0.8597853218184563,9.30285196497645,-31.181335515768165,58.8858072189953,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-30,2.714000186768787,2.8980002403259277,2.714000186768787,2.8980002403259277,12070,0.0,0.0,2.803700089454651,2.561970055103302,3.6702633877595265,3.3634179071421015,9.43531849132413,-30.196561270028376,63.41025980521673,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-01-31,2.898000222752607,3.450000160731626,2.7646002340852593,2.865800142288208,71940,0.0,0.0,2.8202600955963133,2.5781850576400758,3.641781723499298,1.6147463407010965,9.389358503916677,-29.205393035946116,60.88482465094984,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-01,2.760000037521613,2.939399978543891,2.575999991151153,2.805999994277954,150276,0.0,0.0,2.8276200771331785,2.5842800557613375,3.613108390569687,-0.7646035275412335,9.416162959170936,-28.474881558871022,56.39291529553705,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-02,2.7600000276427337,3.394800086643385,2.71400007105104,2.856600046157837,54252,0.0,0.0,2.825320076942444,2.598080050945282,3.5854700565338136,1.107130107865301,8.746459752634763,-27.538648769056305,59.13989107889708,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-05,2.851999922002952,2.865800018561927,2.760000009426764,2.7922000885009766,53197,0.0,0.0,2.8225600719451904,2.6079700529575347,3.5569883902867634,-1.0756186819893274,8.228239382745315,-26.680388947030526,54.439527747776324,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-06,2.8474001120136663,3.022200169917081,2.7830001714921817,2.8519999980926514,44662,0.0,0.0,2.8248600721359254,2.6200450479984285,3.5284683883190153,0.9607529316029102,7.817232924829455,-25.745542834616845,57.794003785103406,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-07,2.916400117799055,3.1556001129300593,2.916400117799055,2.9210000038146973,81199,0.0,0.0,2.8395800590515137,2.633155047893524,3.5025933841864267,2.8673234446638483,7.839455231590929,-24.822702521459068,61.331732105458926,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-08,2.8888001903844867,3.036000054786942,2.88420008494936,2.934800148010254,135554,0.0,0.0,2.8566000699996947,2.648450046777725,3.4776767154534656,2.737522792631155,7.859314676341291,-23.844271234038924,62.01746262265399,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-09,2.9256000428680973,3.0083999633789062,2.9256000428680973,3.0083999633789062,39345,0.0,0.0,2.8740800619125366,2.6604100465774536,3.452146714925766,4.67349198953725,8.031469269557292,-22.9346181877249,65.52850932957698,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-12,3.045199918876018,3.1556000319029156,3.045199918876018,3.059000015258789,83882,0.0,0.0,2.89938006401062,2.681685042381287,3.427575045824051,5.505313126398877,8.117844496608903,-21.76144923074729,67.73662276230343,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-13,3.059000043869019,3.081999912261963,2.966999912261963,3.040600061416626,32373,0.0,0.0,2.91364004611969,2.701235044002533,3.40338671207428,4.357436515399979,7.863255090990813,-20.630969310090624,66.07903898192544,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-14,3.4914000180406592,3.4914000180406592,3.0359999107833566,3.1923999786376953,47609,0.0,0.0,2.9463000297546387,2.722280043363571,3.3809233784675596,8.35284751714683,8.229130832339902,-19.48116716571453,72.13691789311554,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-15,3.256799946304196,3.588000067245862,3.040600044050821,3.339600086212158,123408,0.0,0.0,2.999660038948059,2.7459700465202332,3.35968671242396,11.332619125176322,9.238629268709923,-18.26708019037109,76.51653288038575,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-16,3.3396000647370307,3.3396000647370307,2.8657999739779556,3.1417999267578125,55510,0.0,0.0,3.0281800270080566,2.760230040550232,3.337261708577474,3.7520853693106293,9.707523739739122,-17.290572883275754,62.33716103931765,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-19,2.9256001494623045,3.1188001903718576,2.833600015086513,2.8519999980926514,256744,0.0,0.0,3.034160017967224,2.7712700426578523,3.3127283712228137,-6.003639188305344,9.486263383312908,-16.34478495938667,48.23412958167396,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-20,2.8519999795482263,3.3764001498486875,2.8519999795482263,3.233800172805786,917275,0.0,0.0,3.0723400354385375,2.7911650419235228,3.2922967076301575,5.255282146665196,10.073750182871445,-15.221339697154953,60.812744795638515,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-21,3.5419999437332144,3.5419999437332144,2.957799947316305,3.2200000286102295,63652,0.0,0.0,3.102240037918091,2.8086450397968292,3.2720567087332406,3.7959664388564547,10.453261055106477,-14.162702855960548,60.24293797979978,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-22,3.224600215029949,3.6800001252431396,3.174000151891228,3.362600088119507,60379,0.0,0.0,3.145020031929016,2.831760036945343,3.2536183754603067,6.918240710124725,11.062377846167747,-12.965821120778534,63.99692991830114,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-23,3.3625999640229662,3.3901999376223024,3.1785999206822995,3.321199893951416,22048,0.0,0.0,3.176300024986267,2.852230030298233,3.2348350405693056,4.561907496939786,11.361986629603965,-11.827651347678527,62.16178697651919,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-26,3.3212000223749834,3.362600094047384,3.1878000351473585,3.197000026702881,8285,0.0,0.0,3.1901000261306764,2.870285028219223,3.2154767076174418,0.2162941762228545,11.142273145948595,-10.735318921155988,56.89119662132317,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-27,3.196999939278415,3.4959999856741524,3.196999939278415,3.3856000900268555,26475,0.0,0.0,3.2246000289916994,2.8914450287818907,3.197920044263204,4.992869180290221,11.522093517031532,-9.583573423954219,62.14065242601487,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-28,3.3856001110562506,3.3856001110562506,3.252200126647949,3.252200126647949,8761,0.0,0.0,3.230580043792725,2.9103050351142885,3.1792517145474752,0.669232229573309,11.004860480745414,-8.459433337805647,56.86593654601582,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-02-29,3.3165999590285296,3.3396000463607463,3.0175999204351567,3.243000030517578,57927,0.0,0.0,3.220920038223267,2.928245037794113,3.1614267150561015,0.6855181759337055,9.99489443853475,-7.3758368698371175,56.50967625335772,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-01,3.2292001247406006,3.302800057593231,3.2292001247406006,3.2292001247406006,16716,0.0,0.0,3.2296600580215453,2.9445750415325165,3.144636716445287,-0.014240919251002708,9.681703215845202,-6.361996406978326,55.94352368599404,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-04,3.224600105285645,3.45,3.224600105285645,3.4040000438690186,55368,0.0,0.0,3.284860062599182,2.963090044260025,3.1296100497245787,3.6269423658664404,10.859272365430686,-5.320790859526032,61.24061359758959,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-05,3.4040001712905084,3.4454000236855604,3.2476000952455752,3.312000036239624,4397,0.0,0.0,3.292680048942566,2.9780400454998017,3.1135100503762563,0.5867556826015559,10.56533823036481,-4.351037982359604,57.33340464391911,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-06,3.3258000383240836,3.4959999871935157,3.0543999657222196,3.2200000286102295,3438,0.0,0.0,3.292680048942566,2.990805047750473,3.094573386510213,-2.2073210652725677,10.093436261221626,-3.3532356741670655,53.647363561213446,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-07,3.2107999906110565,3.371799945831299,3.068200017739122,3.371799945831299,245963,0.0,0.0,3.2936000347137453,3.0093200504779816,3.0767483870188395,2.3742989523119213,9.446651717573559,-2.191545360853878,58.39979897041256,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-08,3.3119998656781435,3.390199899673462,3.1785998851020434,3.390199899673462,14100,0.0,0.0,3.3005000352859497,3.0284100472927094,3.055626716216405,2.7177658969405454,8.984582132016076,-0.8907066029778796,58.9492047692008,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-11,3.3901999942143752,3.6800000508626303,3.330399940745034,3.450000047683716,14669,0.0,0.0,3.3258000373840333,3.0493400514125826,3.0368433833122253,3.7344401017378734,9.066223553630328,0.4115018959827771,60.76290242966646,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-12,3.4500000884244706,3.4684000713484595,3.3396001908805344,3.3488001823425293,715,0.0,0.0,3.3221200466156007,3.06601505279541,3.0184433857599893,0.8031057081789963,8.353024672422576,1.5760331056679078,56.234852205304165,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-13,3.2246002309146418,3.445400028945615,3.2246002309146418,3.427000045776367,14369,0.0,0.0,3.3396000385284426,3.0841850519180296,3.0014617164929707,2.6170800766440423,8.281441687539873,2.7561016344301814,58.79038814104158,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-14,3.4270000752617626,3.468400147421321,3.2660001114730743,3.408600091934204,5558,0.0,0.0,3.356160044670105,3.1010900497436524,2.985630049308141,1.5625013874823641,8.225172143825283,3.8671904599254283,57.9331992628065,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-15,3.4684000101444505,3.583400011062622,3.3626000005259287,3.583400011062622,28529,0.0,0.0,3.391580033302307,3.1186850488185884,2.9698750495910646,5.655770345290782,8.750322017514907,5.010648486643037,63.393729998599696,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-18,3.358000141636019,3.634000102196971,3.358000141636019,3.565000057220459,4318,0.0,0.0,3.407680034637451,3.137315046787262,2.954426717758179,4.6166312853297375,8.61771877602964,6.190315296358376,62.47442873966621,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-19,3.5650000095738035,3.5650000095738035,3.4085999389633614,3.5511999130249023,8955,0.0,0.0,3.431600022315979,3.1553700447082518,2.9384033838907877,3.4852514841810103,8.754281548402908,7.3838283064517505,61.7511459280449,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-20,3.403999998220959,3.555799961090088,3.403999998220959,3.555799961090088,10153,0.0,0.0,3.465180015563965,3.1749200403690336,2.9230317155520122,2.615158379048148,9.142276703169925,8.617365438659036,61.90944798063476,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-21,3.404000034471961,3.4683999728775534,3.404000034471961,3.4546000957489014,5157,0.0,0.0,3.4734600305557253,3.192170041799545,2.9075833817323047,-0.5429725588005823,8.811873586709265,9.787738568573292,56.381001006878236,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-22,3.555800135539324,3.555800135539324,3.4040001652228162,3.47760009765625,6538,0.0,0.0,3.482200050354004,3.2082700431346893,2.893093381325404,-0.13209903598979564,8.538246579507595,10.894106074961684,57.31396451821647,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-25,3.408599994557066,3.514400005340576,3.358000151524372,3.514400005340576,19228,0.0,0.0,3.48864004611969,3.225980043411255,2.878603380918503,0.7383954457995221,8.142021933610291,12.06754166952695,58.83122601907666,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-26,3.5650000600079252,3.5650000600079252,3.293599985249149,3.399399995803833,18442,0.0,0.0,3.4937000274658203,3.2385150372982023,2.8645350456237795,-2.699145058838623,7.879691377950534,13.05552160186559,52.545622425499744,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-27,3.3303998851511945,3.3303998851511945,3.2890000344247365,3.321199893951416,11136,0.0,0.0,3.483120012283325,3.2499000310897825,2.8485117117563883,-4.648709138958547,7.17622015946556,14.091159171885545,48.732734854754014,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-03-28,3.321199951706146,3.321199951706146,3.28439998626709,3.28439998626709,1287,0.0,0.0,3.470700001716614,3.261860030889511,2.8344050447146096,-5.367793683043183,6.402481064466527,15.080942188272914,47.00419970475348,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-02,3.2843999839782705,3.6800000508626303,3.2843999839782705,3.450000047683716,2559,0.0,0.0,3.4573600053787232,3.276695030927658,2.8207583765188855,-0.2128779671066159,5.51363409611903,16.163619621027113,54.77757637543775,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-03,3.293600103255895,3.5420000987894342,3.293600103255895,3.440800189971924,15190,0.0,0.0,3.4449400186538695,3.2929100334644317,2.8072650452454884,-0.12017128482728373,4.616888516370696,17.299577360586373,54.30105561037247,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-04,3.4224000263214114,3.4316000175476074,3.3580000877380374,3.4040000438690186,3426,0.0,0.0,3.430220031738281,3.306710034608841,2.7915483792622884,-0.7643820987184748,3.735132377400927,18.454333773097364,52.33966944081092,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-05,3.3672000966373883,3.634000062942505,3.3672000966373883,3.634000062942505,17992,0.0,0.0,3.438040041923523,3.324535036087036,2.7801250437895457,5.69975970696798,3.414161818251786,19.582212444495426,61.66066713104498,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-08,3.6340000531933097,3.7719999219403406,3.6248000619435077,3.7167999744415283,66225,0.0,0.0,3.4642600297927855,3.344085031747818,2.790360043446223,7.289866882880859,3.5936585614318832,19.844212921631406,64.36273585261247,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-09,3.781200177909621,3.9560002330985533,3.7628001951892167,3.9284000396728516,110849,0.0,0.0,3.509340023994446,3.3670850336551665,2.8029717107613883,11.941277072417105,4.224870738855481,20.125544639925913,70.15215984867531,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-10,3.92839994403551,3.9376001545168275,3.7719998753745587,3.9007997512817383,33211,0.0,0.0,3.547979998588562,3.38813002705574,2.8155450423558555,9.944243001187528,4.717940877603511,20.336559212733633,68.58701192452179,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-11,3.8823997666303995,3.8823997666303995,3.5880000504515217,3.670799970626831,22372,0.0,0.0,3.5751199960708617,3.4038850247859953,2.8262017091115315,2.6762730946408455,5.030574477045743,20.440271966860752,57.14524872110171,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-12,3.6800001252299595,3.8548001838212067,3.5420000327957957,3.643200159072876,43877,0.0,0.0,3.607320022583008,3.415155029296875,2.8377017100652058,0.994648000877287,5.6268307481694775,20.34933119233312,55.93929283134793,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-15,3.6340001906357857,3.6340001906357857,3.5420000553131104,3.5420000553131104,18467,0.0,0.0,3.6330800294876098,3.4202150285243986,2.848243377606074,-2.506963057110109,6.223731525296777,20.08155817776577,51.63634286886021,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-16,3.5420000553131104,3.772000064602146,3.5420000553131104,3.5420000553131104,3935,0.0,0.0,3.642280030250549,3.430220031738281,2.8600117107232412,-2.7532197992624035,6.182110667833909,19.937272245323967,51.63634286886021,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-17,3.6248001990380283,3.6248001990380283,3.5420000553131104,3.5420000553131104,31934,0.0,0.0,3.652400016784668,3.4474700331687926,2.871205043792725,-3.022668956418045,5.944358664301744,20.070492374687714,51.6363428688602,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-18,3.5420000553131104,3.716800115015602,3.5420000553131104,3.5420000553131104,2408,0.0,0.0,3.6662000179290772,3.4551750302314757,2.882321709394455,-3.3877028533245057,6.107504999058302,19.87471832064753,51.6363428688602,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-19,3.5420000553131104,3.6524001738313,3.5420000553131104,3.5420000553131104,39034,0.0,0.0,3.657000017166138,3.4632250308990478,2.893093377351761,-3.1446530301671327,5.595217883279922,19.706645420106213,51.6363428688602,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-22,3.5696000754448667,3.5696000754448667,3.2659999288282093,3.4223999977111816,6237,0.0,0.0,3.627560019493103,3.4647200286388395,2.902561710278193,-5.655592758754393,4.699946590438862,19.36766120665069,45.628001260904604,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-23,3.422400119681109,3.532800017407065,3.422400119681109,3.496000051498413,9353,0.0,0.0,3.5843200206756594,3.4690900325775145,2.91218337615331,-2.4640648342721803,3.321619993025365,19.123337526904642,49.52064255367732,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-24,3.5696002026608156,3.578800194137979,3.496000051498413,3.496000051498413,2435,0.0,0.0,3.5438400506973267,3.476565033197403,2.91973504225413,-1.3499480370029686,1.935100216953248,19.071250743128456,49.52064255367732,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-25,3.496000110342146,3.5788002543753814,3.459200143814087,3.459200143814087,15148,0.0,0.0,3.522680068016052,3.478405034542084,2.9292800426483154,-1.8020348988921007,1.2728544558295505,18.746073570941796,47.54673088924796,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-26,3.45920001024909,3.5603999142937695,3.45920001024909,3.468400001525879,5340,0.0,0.0,3.5052000522613525,3.483810031414032,2.937981708844503,-1.0498701981854723,0.6139835597935469,18.57834311651318,48.10365659709519,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-29,3.468400030390421,3.5327999698638908,3.413200082270305,3.450000047683716,6541,0.0,0.0,3.496000051498413,3.4889850318431854,2.9470667084058126,-1.3157895634178067,0.2010619017050273,18.3883969063774,47.02817462788128,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-04-30,3.4499999510098824,3.4499999510098824,3.3580000400543213,3.3580000400543213,675,0.0,0.0,3.4776000499725344,3.4922050297260285,2.9545417090257007,-3.4391536749361866,-0.41821656028712517,18.197858539544175,41.97492466225945,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-02,3.321199931554171,3.4959999856741524,3.321199931554171,3.3856000900268555,4075,0.0,0.0,3.461960053443909,3.4917450308799745,2.9615183770656586,-2.205685861137869,-0.8530112357189893,17.903878561769275,43.92169285930665,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-03,3.3672001538263903,3.505200025287453,3.3672001538263903,3.4316000938415527,8233,0.0,0.0,3.450920057296753,3.4947350323200226,2.968648378054301,-0.559849638195748,-1.2537424044472512,17.721420231335276,47.106848485517006,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-06,3.431600115812948,3.6340001479301707,3.330399990081787,3.330399990081787,10999,0.0,0.0,3.429760050773621,3.4974950313568116,2.9750500440597536,-2.896997434832851,-1.9366712454460255,17.56088064267079,41.51961463116747,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-07,3.311999912261963,3.4224000263214114,3.2383999824523926,3.4040000438690186,79237,0.0,0.0,3.4279200553894045,3.4983000338077543,2.9827550450960794,-0.6977995733237324,-2.01183368316594,17.284187971093296,46.49041413156027,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-08,3.2383999824523926,3.4040000438690186,3.2383999824523926,3.4040000438690186,14698,0.0,0.0,3.4187200546264647,3.4986450374126434,2.9909967124462127,-0.43057081370338895,-2.2844553228893942,16.972547072819953,46.49041413156027,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-10,3.3764000112019206,3.3764000112019206,3.1923999705475357,3.2751998901367188,25331,0.0,0.0,3.3966400384902955,3.4942750334739685,2.997590043147405,-3.575302268637016,-2.7941416759803652,16.569476919033765,39.6502091149906,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-13,3.174000100596198,3.2660000145024255,3.174000100596198,3.2016000747680664,6570,0.0,0.0,3.3708800315856933,3.4905950307846068,3.0036467095216115,-5.0218327330384405,-3.429644462995877,16.211904007197674,36.358255077647485,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-14,3.20160002722337,3.2843999485093716,3.137200088445369,3.155600070953369,4145,0.0,0.0,3.3396000385284426,3.483810031414032,3.008208376169205,-5.50964083879191,-4.139433309658863,15.810130010025459,34.434004444355125,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-15,3.1096000855705417,3.1096000855705417,2.9348000340359652,3.0083999633789062,39709,0.0,0.0,3.2954400300979616,3.4738050282001494,3.0123100419839224,-8.710219700478746,-5.134571360632821,15.320301688211485,29.12245186281126,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-16,3.0083999920478233,3.118800106459398,2.971600027025663,2.990000009536743,32847,0.0,0.0,3.2586400270462037,3.4589700281620024,3.016526707013448,-8.243930451961257,-5.791608469711092,14.667309927005459,28.5300321456548,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-17,2.7599999744551518,3.1188000676461614,2.7599999744551518,3.0911998748779297,61486,0.0,0.0,3.229200005531311,3.4471250236034394,3.02243004043897,-4.273508312182594,-6.321935426766776,14.05144130657158,36.215409944637905,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-20,2.9072001616547776,3.1372001681967507,2.9072001616547776,3.0176000595092773,29106,0.0,0.0,3.1878000020980837,3.433785027265549,3.028410041332245,-5.339103534625368,-7.1636699215079345,13.385736422765698,33.40222367995878,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-21,3.0176000644929966,3.0268000559960657,2.8519999980926514,2.8519999980926514,22340,0.0,0.0,3.13996000289917,3.416190028190613,3.032780041297277,-9.170817607251083,-8.085909244274331,12.642195664454833,28.111064507769996,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-22,2.8519999029651384,2.925600051879883,2.8519999029651384,2.925600051879883,10875,0.0,0.0,3.0921200037002565,3.402965027093887,3.037533374627431,-5.385300428867695,-9.134534763617319,12.030539500204771,33.1774779906345,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-23,3.2107999884170857,3.2107999884170857,2.9256000428680973,3.0083999633789062,6293,0.0,0.0,3.052559995651245,3.3912350237369537,3.0436667064825693,-1.4466556704946107,-9.986775487842996,11.419394788335865,38.434194630719645,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-24,3.0084001408531496,3.0084001408531496,2.8520000624278143,2.8980002403259277,13813,0.0,0.0,3.014840030670166,3.3758250296115877,3.049033373594284,-3.8754888868271395,-10.69323782408698,10.717877306540357,34.5333939292573,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-27,2.898000122976443,3.201600056477655,2.851999946941027,3.137200117111206,16478,0.0,0.0,3.00840003490448,3.369270032644272,3.0565850416819256,4.281348248648569,-10.71062854100102,10.229880297728847,47.06849570995715,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-28,3.2200000689233628,3.2200000689233628,3.0176000382696255,3.118800163269043,9858,0.0,0.0,3.0047200441360475,3.3642100393772125,3.06409837603569,3.7966971117869015,-10.685717925855613,9.794452609246992,46.3335686232738,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-29,3.118800056099891,3.118800056099891,2.944000005722046,2.944000005722046,3365,0.0,0.0,2.9982800483703613,3.3557000398635863,3.067280042171478,-1.8103726727534328,-10.651130531552354,9.403119171600698,39.95155923482557,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-30,2.9256001275499295,3.0727999904965286,2.9256001275499295,2.953200101852417,18141,0.0,0.0,2.9946000576019287,3.343280041217804,3.072685041030248,-1.3824869749940745,-10.42927841273108,8.806467196417483,40.41673939332021,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-05-31,2.9900001509756615,3.2108001708984375,2.925600209140507,3.2108001708984375,17480,0.0,0.0,3.0065600872039795,3.3375300407409667,3.0794700423876447,6.7931482415306,-9.916613468548988,8.38001327505161,51.699373506991776,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-03,3.0543999961506234,3.1648001122908176,2.925600116556343,3.0360000133514404,12261,0.0,0.0,3.008400082588196,3.3283300399780273,3.085028374195099,0.9174288660270137,-9.612326708800298,7.8865292720818925,45.41494792984407,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-04,3.0176001184957983,3.0176001184957983,2.870400032467307,2.980800151824951,11324,0.0,0.0,3.0212800979614256,3.3120000422000886,3.089896708726883,-1.3398276500013293,-8.77777598231986,7.188050424012975,43.61206387174377,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-05,3.1648000526428226,3.1648000526428226,2.9072000789642334,3.0727999210357666,12238,0.0,0.0,3.0360000848770143,3.2959000408649444,3.0961450397968293,1.2121157816187278,-7.885553347052491,6.451732670806116,47.362628110487364,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-07,2.944000005722046,2.9807999701499943,2.9072000412940975,2.944000005722046,13775,0.0,0.0,3.029560089111328,3.2712900400161744,3.0995950400829315,-2.8241751565449187,-7.389438048839322,5.539271992403533,43.045890702688276,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-10,2.9624001105820272,3.0176000595092773,2.8519999933824285,3.0176000595092773,7816,0.0,0.0,3.0415200710296633,3.2492100477218626,3.10634170571963,-0.7864492412272045,-6.392014478652072,4.599247460096641,46.07065950309244,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-11,2.8520000210861456,2.9992001056671143,2.778400088468212,2.9992001056671143,4709,0.0,0.0,3.027720069885254,3.23242005109787,3.112513373295466,-0.9419617256499079,-6.332715982970432,3.852406830800186,45.421204521048956,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-12,2.8519999593382397,2.907200126951667,2.760000045557689,2.8888001441955566,9468,0.0,0.0,3.0047200679779054,3.213560050725937,3.1169983744621277,-3.8579275659565737,-6.4987110697015,3.0979058909670454,41.62927431314832,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-13,2.8519998731044756,2.8519998731044756,2.7415999799058923,2.77839994430542,56662,0.0,0.0,2.9881600618362425,3.1944700479507446,3.120218374331792,-7.0197082214506175,-6.458347801597018,2.3796947748842663,38.19529860098444,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-14,2.7784000909491726,2.907200192490669,2.6864001750946045,2.6864001750946045,4272,0.0,0.0,2.9614800691604612,3.173080050945282,3.121176707744598,-9.288595149783943,-6.668598912964191,1.6629415140737,35.56264344452522,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-17,2.6864002345667926,2.9072002568509823,2.6128000809086585,2.6496002674102783,14474,0.0,0.0,2.9053600788116456,3.150770056247711,3.123170044024785,-8.803033168473167,-7.788888844790122,0.8837178838766686,34.53719047561684,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-18,2.6680002618719056,2.7784001637917934,2.4840002059936523,2.4840002059936523,11471,0.0,0.0,2.850160098075867,3.1243200600147247,3.123553377389908,-12.846993834816779,-8.775028059627344,0.02454520644232977,30.3026972206153,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-19,2.484000061150365,2.7416000366210938,2.484000061150365,2.7416000366210938,29188,0.0,0.0,2.826240086555481,3.1043100595474242,3.125393376747767,-2.9947933417625308,-8.957545079517057,-0.6745812337479834,42.178740013698125,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-20,2.7232001170496822,2.98080009848072,2.668000168031267,2.8519999980926514,98224,0.0,0.0,2.8041600942611695,3.090050059556961,3.128843375047048,1.7060332585642384,-9.251952550463894,-1.239861215152826,46.39447559386463,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-24,2.8519999593382397,3.7903999572802465,2.8519999593382397,2.8888001441955566,285608,0.0,0.0,2.7986401081085206,3.07487006187439,3.1320633749167124,3.221565925029614,-8.983467535453645,-1.8260586136397523,47.76170107168226,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-25,2.9624000160853066,3.311999900817871,2.4472000705083206,2.759999990463257,166654,0.0,0.0,2.7728801012039184,3.0564700603485107,3.134440040588379,-0.4645029813971868,-9.278348995581402,-2.4875250197873386,43.572822169824086,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-26,2.7231999977061285,2.77839994430542,2.428800063164817,2.77839994430542,63079,0.0,0.0,2.750800085067749,3.039450055360794,3.1364333728949227,1.0033393334358198,-9.496782807269426,-3.0921529649652064,44.324048331367,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-27,2.594400070414823,2.815200090408325,2.594400070414823,2.815200090408325,3075,0.0,0.0,2.7434400796890257,3.0231200575828554,3.139078374703725,2.615694479736318,-9.251368538682803,-3.6940242733446897,45.876040158438435,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-06-28,2.760000138118345,2.8152000882378867,2.4656001848023505,2.6680002212524414,23620,0.0,0.0,2.732400107383728,3.0035700619220735,3.1402667105197906,-2.356898096924367,-9.02825467519862,-4.3530267075655615,40.957888623036744,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-01,2.668000020047163,2.925599987190082,2.4655999988609225,2.631199836730957,40581,0.0,0.0,2.7268800735473633,2.9854000568389893,3.1407267093658446,-3.508780519707163,-8.659475392566081,-4.945564097113621,39.8088741659573,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-02,2.631200064486915,2.8520000867711053,2.631200064486915,2.6496002674102783,36255,0.0,0.0,2.7268800735473633,2.9670000612735747,3.1406117121378583,-2.834000911398815,-8.0930226750026,-5.52795655041685,40.70458811494429,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-03,2.5576001301738875,2.6864002345667926,2.5392001465956304,2.6496002674102783,49319,0.0,0.0,2.7434400796890257,2.947450065612793,3.1400750478108725,-3.4205161969269002,-6.921575646145926,-6.134406957323191,40.70458811494429,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-04,2.6864001786863705,2.8336000442504883,2.649600212295341,2.8336000442504883,13667,0.0,0.0,2.7526400804519655,2.9350300669670104,3.1411100486914316,2.9411750694711123,-6.21424593116766,-6.560737399514957,49.43175750927684,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-05,2.833600015086513,2.944000132468443,2.760000083061959,2.8519999980926514,3978,0.0,0.0,2.7526400804519655,2.921230065822601,3.1429500500361125,3.6096225709382104,-5.77119848734549,-7.054518229170196,50.22077130947952,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-08,2.8519999309732933,2.9256000806108307,2.7967999832539614,2.9072000980377197,4874,0.0,0.0,2.754480075836182,2.9088100671768187,3.145288383960724,5.544422831055565,-5.305605652362986,-7.518493947639819,52.60970432015582,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-09,2.925600081770212,2.925600081770212,2.6496001237190816,2.7416000366210938,38366,0.0,0.0,2.7526400804519655,2.895470070838928,3.1463617185751596,-0.4010710993156453,-4.932877456598239,-7.9740242914552315,45.547705716195374,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-10,2.7416001547451643,2.8152000882378867,2.6680002212524414,2.6680002212524414,10968,0.0,0.0,2.7416001081466677,2.8821300745010374,3.1462467193603514,-2.684559526953771,-4.875906455356589,-8.39465777537657,42.798000362585874,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-11,2.6680002212524414,2.7416001547451643,2.6680002212524414,2.6680002212524414,4426,0.0,0.0,2.726880121231079,2.8699400782585145,3.1459783871968585,-2.159240500534199,-4.984771567573796,-8.774323118738927,42.79800036258588,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-12,2.6680002509885354,2.6680002509885354,2.5392001465956304,2.6496002674102783,10793,0.0,0.0,2.7250401258468626,2.860970085859299,3.1452883879343667,-2.7683944071517037,-4.751184246360594,-9.039498672545916,42.06176525359451,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-15,2.5576001301738875,2.6496002674102783,2.5392001465956304,2.6496002674102783,41766,0.0,0.0,2.726880168914795,2.852460092306137,3.143371723095576,-2.834004309594266,-4.402512895099408,-9.254763878290237,42.06176525359451,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-16,2.704800187998803,2.760000138118345,2.594400068414615,2.6680002212524414,17051,0.0,0.0,2.7287201642990113,2.8418801009654997,3.1421067237854006,-2.2252169292034543,-3.9818687856691577,-9.554946703344559,43.19507443618959,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-17,2.5575999914719754,2.760000019201496,2.5575999914719754,2.7416000366210938,7438,0.0,0.0,2.737920141220093,2.8349801003932953,3.141378390789032,0.1344047748361654,-3.4236557484032195,-9.753625710743407,47.609557827198,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-18,2.7232000552586153,2.7232000552586153,2.5392000100272045,2.5759999752044678,40014,0.0,0.0,2.7121601343154906,2.828080099821091,3.1397300561269126,-5.020358399500909,-4.098892584864677,-9.926011177224096,40.06509210667432,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-19,2.594400039894935,2.6864001750946045,2.5760000567240215,2.6864001750946045,1606,0.0,0.0,2.695600152015686,2.8221001029014587,3.1390783905982973,-0.3412960529105953,-4.482475683825514,-10.097813697364327,46.187364564885996,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-22,2.686400145965369,2.7416000948795647,2.576000028791879,2.7048001289367676,10501,0.0,0.0,2.675360155105591,2.8145101070404053,3.1380050579706826,1.1004116128063754,-4.944020331877126,-10.30893656810988,47.15621838732947,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-23,2.576000113752144,2.6864002345667926,2.576000113752144,2.6496002674102783,26188,0.0,0.0,2.6661601781845095,2.808300107717514,3.136701726913452,-0.6211146243099097,-5.061422358044591,-10.46964766774585,44.56404223723359,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-24,2.6680001629939705,2.723200111908166,2.631199977706075,2.7048001289367676,7327,0.0,0.0,2.669840168952942,2.797490108013153,3.1350917259852094,1.3094401826134823,-4.563016637469756,-10.768476570361411,47.66234923882167,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-25,2.704800100004351,2.7784000311026693,2.668000134455192,2.7232000827789307,8036,0.0,0.0,2.675360155105591,2.7876001060009004,3.133903392155965,1.7881677568548346,-4.0264007256165995,-11.050222129432836,48.69174776700986,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-26,2.7232001414364317,2.7416001246073454,2.594400039894935,2.6864001750946045,8293,0.0,0.0,2.6790401458740236,2.781160110235214,3.132906726996104,0.274726350477279,-3.671847729491339,-11.227484486847516,46.712863098800455,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-29,2.6864001750946045,2.6864001750946045,2.5760000567240215,2.6864001750946045,12751,0.0,0.0,2.6827201366424562,2.774490112066269,3.131488394737244,0.1371756375882723,-3.307633897295384,-11.400274810883657,46.71286309880045,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-30,2.6864000603155036,2.6864000603155036,2.5759999466618746,2.594399929046631,18494,0.0,0.0,2.675360107421875,2.7590801060199737,3.129840060075124,-3.026141346379787,-3.034344614186156,-11.8459712617472,41.788667763494985,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-07-31,2.5760000041577453,2.594399986953186,2.5576000213623047,2.5576000213623047,68326,0.0,0.0,2.656960105895996,2.7471201062202453,3.1273867269357045,-3.739615220913702,-3.2819824703005063,-12.159245207517218,39.97351353206243,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-01,2.5024000448499413,2.5759999752044678,2.5024000448499413,2.5759999752044678,9917,0.0,0.0,2.656960105895996,2.737000101804733,3.124511726697286,-3.0470962101339696,-2.9243694896452483,-12.402309825931285,41.34538024322611,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-02,2.557599992615836,2.5759999752044678,2.5024000448499413,2.5759999752044678,11277,0.0,0.0,2.6459200859069822,2.7245801031589507,3.121521725257238,-2.6425632079718273,-2.8870510050619527,-12.716285742511563,41.34538024322611,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-05,2.1711999687250083,2.5760000335306352,2.1711999687250083,2.5392000675201416,88462,0.0,0.0,2.62936007976532,2.714460104703903,3.1176117261250815,-3.428971670294216,-3.1350626517263254,-12.931424976459802,39.26394779612941,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-06,2.5024000448499413,2.5759999752044678,2.465600079672678,2.5759999752044678,19209,0.0,0.0,2.622000050544739,2.703420102596283,3.1135867257912953,-1.7543888044820721,-3.0117424951212968,-13.17344462569198,42.3874178996789,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-07,2.465600222340338,2.557600140606911,2.447200238687023,2.4840002059936523,4829,0.0,0.0,2.599920058250427,2.6905401051044464,3.1089483936627706,-4.458592943614626,-3.3680987204798196,-13.458193433226514,37.232333897983146,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-08,2.5024000448499413,2.5759999752044678,2.5024000448499413,2.5759999752044678,3074,0.0,0.0,2.585200047492981,2.6827201008796693,3.1038117269674936,-0.3558746758277031,-3.635118451407257,-13.56691910237874,44.501205804337665,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-09,2.5760000041577453,2.7232000858663667,2.5576000213623047,2.5576000213623047,504,0.0,0.0,2.572320032119751,2.677200102806091,3.0972950597604116,-0.5722464768629862,-3.9175282630689803,-13.563285022861738,43.418232249732256,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-12,2.5576001016682537,2.6680002212524414,2.4656001848023505,2.6680002212524414,46448,0.0,0.0,2.5704800367355345,2.676740103960037,3.0933467288812,3.793851075410641,-3.969756610561437,-13.467828259648124,51.10659958346192,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-13,2.686400204625622,2.686400204625622,2.6680002212524414,2.6680002212524414,180,0.0,0.0,2.577840065956116,2.677200102806091,3.091813397407532,3.49750771923414,-3.7113414401049734,-13.410036160302935,51.10659958346191,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-14,2.6680002509885354,2.7968001360363344,2.5944000973304013,2.6496002674102783,27593,0.0,0.0,2.587040090560913,2.681340104341507,3.086945064862569,2.4182144326878694,-3.5168986443721795,-13.139364387720958,49.798648769495756,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-15,2.8151999376297,2.8151999376297,2.6127999120076497,2.759999990463257,21332,0.0,0.0,2.605440092086792,2.681800103187561,3.0831117312113445,5.932199279725983,-2.847341642280057,-13.016447764807712,56.92230308722254,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-16,2.704800071460289,2.760000019201496,2.668000106299484,2.7416000366210938,25392,0.0,0.0,2.6220000982284546,2.679040104150772,3.077936730782191,4.5614009882549755,-2.1291210174100246,-12.959870897997567,55.50852720943301,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-19,2.6680002509885354,2.7416001853015635,2.576000113752144,2.6496002674102783,41322,0.0,0.0,2.633040118217468,2.67306010723114,3.0723400672276813,0.6289364555531812,-1.4971600865019883,-12.99595589224049,48.96065744861799,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-20,2.6311999525440672,2.6311999525440672,2.520800055771424,2.5576000213623047,16965,0.0,0.0,2.6312001228332518,2.6680001080036164,3.0670117338498435,-2.7972065230711216,-1.3793097331581805,-13.009784783097999,43.441959003446144,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-21,2.5576000213623047,2.6127999697486266,2.4840000901805426,2.5576000213623047,4903,0.0,0.0,2.638560104370117,2.6624801099300384,3.0601117332776386,-3.0683433314148174,-0.8984106762228506,-12.994023029404328,43.441959003446144,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-22,2.5576001101381607,2.6680002300879564,2.5024001598358154,2.5024001598358154,14366,0.0,0.0,2.6312001228332518,2.654660111665726,3.053863400220871,-4.895103260285111,-0.8837285319269564,-13.072074164360878,40.2824225540882,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-23,2.7232001713719836,2.7232001713719836,2.6312000351609766,2.6680002212524414,22010,0.0,0.0,2.6422401428222657,2.654660111665726,3.0490717351436616,0.9749332777398683,-0.4678553306647944,-12.935465536344704,51.64469680903953,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-26,2.594399900705042,2.649600066601388,2.5391999541537853,2.612799882888794,13526,0.0,0.0,2.6367201089859007,2.6542001128196717,3.043935066461563,-0.9071962555140761,-0.6585789726005721,-12.803655305792732,48.34281906961944,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-27,2.5575999914719754,2.8151999669427035,2.52080002631117,2.7416000366210938,8327,0.0,0.0,2.644080090522766,2.656500107049942,3.0384150664011638,3.6882372227630578,-0.4675330708331371,-12.569545338766996,55.493083284073705,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-28,2.7416000686618074,2.7416000686618074,2.5576000213623047,2.5576000213623047,10216,0.0,0.0,2.6348800659179688,2.6542001008987426,3.0321283996105195,-2.9329625114735682,-0.7279042365431246,-12.464125818692978,45.75051355873062,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-29,2.576000093572276,2.6680002300879564,2.4288002260993546,2.5024001598358154,41942,0.0,0.0,2.609120082855225,2.645920103788376,3.026148400704066,-4.090264902741582,-1.3908213207368438,-12.564760433666303,43.2948133275606,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-08-30,2.50240001712285,2.6496000955459915,2.50240001712285,2.594399929046631,3627,0.0,0.0,2.5944000720977782,2.639480102062225,3.0196700672308605,-5.513843023310258e-06,-1.7079132337169702,-12.590447191380823,48.27780077767687,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-02,2.520800084514895,2.5392000675201416,2.428800169488661,2.5392000675201416,16957,0.0,0.0,2.5833600521087647,2.630280101299286,3.0125784019629163,-1.709401078358237,-1.7838423051348733,-12.690069756011496,45.68382790775777,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-03,2.4288002260993546,2.5392001267040456,2.3920000398860197,2.5024001598358154,23702,0.0,0.0,2.577840065956116,2.624300104379654,3.00468173623085,-2.9264773682660516,-1.7703782561301526,-12.659631376744631,43.987007823246735,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-04,2.502400101509648,2.5392000675201416,2.465600135499155,2.5392000675201416,5090,0.0,0.0,2.5760000705718995,2.6210801005363464,2.9979350686073305,-1.4285715079032553,-1.7199027971416172,-12.570484665168195,46.141344142723845,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-05,2.576000093572276,2.6312000438746215,2.355200073017789,2.5024001598358154,11849,0.0,0.0,2.5760000705718995,2.6169400990009306,2.9902300695578257,-2.857139313654759,-1.564423597034597,-12.483653828419113,44.30618484417955,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-06,2.502400006817696,2.520799989126679,2.41039987592769,2.447200059890747,3195,0.0,0.0,2.55392005443573,2.6118800938129425,2.98221840262413,-4.178674048924442,-2.219092657220718,-12.418215529932933,41.6314375751316,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-09,2.447200059890747,2.447200059890747,2.2632000174558256,2.447200059890747,21703,0.0,0.0,2.5373600721359253,2.6068200886249544,2.972750069697698,-3.553299873962405,-2.664549686114621,-12.30947683099223,41.6314375751316,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-10,2.2448000351468425,2.520799989126679,2.2448000351468425,2.447200059890747,25525,0.0,0.0,2.5079200744628904,2.6013000845909118,2.9634350697199503,-2.4211303697605873,-3.5897438623543714,-12.220108644501561,41.631437575131606,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-11,2.5391999076661604,2.5391999076661604,2.2447999787709048,2.3183999061584473,36115,0.0,0.0,2.484000062942505,2.5907200813293456,2.9531617363293967,-6.666672809496249,-4.119318762221531,-12.273003897529309,35.402879086595945,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-12,2.336799945369844,2.336799945369844,2.2264000515783984,2.281599998474121,49539,0.0,0.0,2.4619200468063354,2.583360081911087,2.942543403307597,-7.324366547407986,-4.700855910683358,-12.206559841828192,33.84485616340015,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-13,2.299999952316284,2.336799916458131,2.2264000240325914,2.299999952316284,10934,0.0,0.0,2.432480049133301,2.573700076341629,2.9329217354456585,-5.4462973648733435,-5.487042896197312,-12.247911519856682,35.37623350052,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-16,2.226400079572104,2.263200044631958,2.152799930107302,2.263200044631958,60688,0.0,0.0,2.4048800468444824,2.562660074234009,2.922801735003789,-5.891354223609911,-6.156884753304148,-12.321795777547443,33.696213773074476,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-17,2.208000069279824,2.281599998474121,2.1711998853375842,2.281599998474121,15939,0.0,0.0,2.382800030708313,2.553460067510605,2.9125284016132356,-4.247105545156004,-6.683481718540067,-12.32840627077643,35.349430653908755,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-18,2.2080001831054688,2.318400082588191,2.2080001831054688,2.2080001831054688,19237,0.0,0.0,2.349680042266846,2.5410400688648225,2.9026000698407493,-6.029751141125235,-7.530775643512948,-12.456418117421313,31.920876705986743,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-19,2.318399992221739,2.3367999747516657,2.263200044631958,2.263200044631958,19208,0.0,0.0,2.32576003074646,2.529540067911148,2.8937834044297537,-2.689872785130934,-8.05601143661529,-12.587097429649646,36.86664092095408,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-20,2.3183999061584473,2.3183999061584473,2.226399996924019,2.3183999061584473,2793,0.0,0.0,2.31288001537323,2.5203400611877442,2.8857334037621816,0.2386587608750837,-8.231430710852004,-12.662061647762318,41.44752590285881,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-23,2.300000009691812,2.300000009691812,2.2080000970421767,2.263200044631958,4921,0.0,0.0,2.294480013847351,2.509760057926178,2.8758434037367504,-1.3632705025372216,-8.5777141682904,-12.729599439764314,38.443535793979194,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-24,2.2632000735548674,2.2632000735548674,2.1711999403844087,2.244800090789795,8976,0.0,0.0,2.274240016937256,2.501020061969757,2.8658767362435658,-1.2944951248860712,-9.067502035705115,-12.731066540986093,37.46869896434796,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-25,2.097600009324119,2.3184000218500844,2.097600009324119,2.244800090789795,4260,0.0,0.0,2.2668800354003906,2.4932000637054443,2.8562167366345723,-0.9740235153950616,-9.07749167825274,-12.709703303428713,37.46869896434796,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-26,2.20800012525965,2.244800090789795,2.20800012525965,2.244800090789795,11509,0.0,0.0,2.263200044631958,2.4849200665950777,2.8446400701999663,-0.8130060745538422,-8.922621896121111,-12.645536683999598,37.46869896434796,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-27,2.244800090789795,2.2632000735548674,2.097600009324119,2.244800090789795,17569,0.0,0.0,2.257680058479309,2.4766400694847106,2.8323734045028686,-0.5704957016004135,-8.841010597513199,-12.559549332465062,37.46869896434796,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-09-30,2.244800069264004,2.7600000204358786,2.189600121498109,2.5759999752044678,73167,0.0,0.0,2.2889600515365602,2.4775600671768188,2.821103403965632,12.540189308905585,-7.612328683323039,-12.177622993396609,61.25532357635636,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-01,2.502399977925999,2.723199982429619,2.3919998660016444,2.46560001373291,71782,0.0,0.0,2.307360053062439,2.4748000681400297,2.8091434061527254,6.858052364235374,-6.76579967946391,-11.901967599105133,53.89574029236843,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-02,2.520799989126679,2.557599953744645,2.428800077581764,2.447200059890747,20501,0.0,0.0,2.3312800407409666,2.4738800644874575,2.7989467402299244,4.972376425139247,-5.764225428447961,-11.613892864419556,52.75803316805464,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-03,2.4472002187864117,2.539200136304842,2.3368000984191895,2.3368000984191895,17245,0.0,0.0,2.33864004611969,2.4679000675678253,2.7880600730578107,-0.07867596826427124,-5.237652170232486,-11.483253484522276,46.42560233608528,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-04,2.4472002187864117,2.50240016929747,2.226400197397073,2.3368000984191895,26097,0.0,0.0,2.3404800653457642,2.4623800694942473,2.7780167400836944,-0.15723128690827565,-4.950495078264676,-11.361942713849082,46.42560233608528,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-07,2.300000073928244,2.6496001904509847,2.226400141752972,2.3736000061035156,7127,0.0,0.0,2.35152006149292,2.455020064115524,2.768280073006948,0.93896475612365,-4.215851598748236,-11.316051867221509,48.80128324802968,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-08,2.281599998474121,2.336799945369844,2.1343999207404356,2.281599998474121,19450,0.0,0.0,2.3552000522613525,2.445360058546066,2.757776739199956,-3.1250022144218335,-3.686982862487741,-11.328570446370632,43.596439986308994,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-09,2.4839999923706046,2.4839999923706046,2.2264000240325914,2.299999952316284,8631,0.0,0.0,2.3607200384140015,2.4366200506687163,2.7474267383416495,-2.5721002537221973,-3.114971176317972,-11.312646970180413,44.86302088794411,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-10,2.171199912013429,2.428800106048584,2.171199912013429,2.428800106048584,19736,0.0,0.0,2.37912003993988,2.4283400535583497,2.7381500720977785,2.0881697970128146,-2.0268995500175246,-11.314574087682276,52.84543875209307,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-11,2.2080000705288763,2.447200059890747,2.2080000705288763,2.447200059890747,25226,0.0,0.0,2.3993600368499757,2.4209800541400908,2.7300234059492747,1.993865960340769,-0.8930274850114085,-11.320172242322752,53.87282415659073,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-14,2.4472002187864117,2.4472002187864117,2.244800180900759,2.3368000984191895,11044,0.0,0.0,2.3754400491714476,2.4131600499153136,2.7203634063402813,-1.6266439039678444,-1.5630956904491182,-11.292732276466323,47.22447669126204,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-15,2.3368000349722586,2.355200017976363,2.189600170939423,2.226400136947632,36672,0.0,0.0,2.35152006149292,2.404880052804947,2.709783407052358,-5.320810423613934,-2.218821319166846,-11.251945578155192,41.68455282512627,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-16,2.2264000240325914,2.355199898529054,2.097599930191041,2.299999952316284,48172,0.0,0.0,2.336800050735474,2.398440051078796,2.700123405456543,-1.5748073271227176,-2.5700037954084904,-11.172946901911601,46.21451155761446,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-17,2.300000039085012,2.336800004615157,2.2264001080247224,2.244800090789795,4190,0.0,0.0,2.327600049972534,2.392000049352646,2.689926739533742,-3.557310422970481,-2.692307610843931,-11.075643280632143,43.4861167776664,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-18,2.300000009691812,2.300000009691812,2.226400079572104,2.263200044631958,4751,0.0,0.0,2.320240044593811,2.381880044937134,2.680036739508311,-2.458366326999522,-2.587871730750813,-11.125097286012505,44.65895900880469,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-21,2.263200163240188,2.263200163240188,2.1896002292633057,2.1896002292633057,7705,0.0,0.0,2.30184006690979,2.3713000535964968,2.670300074418386,-4.876091925759458,-2.9291943287125703,-11.197244223086567,40.99415263512296,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-22,2.1896000276875225,2.2080000094878307,2.134399862941513,2.1527998447418213,9554,0.0,0.0,2.2889600515365602,2.3565800487995148,2.6600267390410104,-5.9485619551698035,-2.8694122780765037,-11.40765563698408,39.259366123040635,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-23,2.244800090789795,2.4840000860808322,2.244800090789795,2.244800090789795,76593,0.0,0.0,2.2834400653839113,2.348760050535202,2.6501367390155792,-1.6921825617358566,-2.7810412194471166,-11.372118428588198,45.471861910646076,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-24,2.1527998764038103,2.7231999786376946,2.1527998764038103,2.299999952316284,19344,0.0,0.0,2.270560050010681,2.3437000453472137,2.6415500720342,1.2965921031449763,-3.1207063157135826,-11.275577542151929,48.85210720211981,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-25,2.3183999306580105,2.3183999306580105,2.1159999088583317,2.134399890899658,113114,0.0,0.0,2.239280033111572,2.3322000443935393,2.630970070759455,-4.683654597061655,-3.984221315205831,-11.355888449148074,40.70063703750502,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-28,2.0792000664112167,2.0792000664112167,1.453600092045097,1.5824000835418701,885885,0.0,0.0,2.1638400316238404,2.3082800447940826,2.6157900710900623,-26.87074550726526,-6.257473545985073,-11.75591381336779,25.4540497056132,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-29,1.5732000350952149,1.7020000219345093,1.4995999956130983,1.6191999912261963,181711,0.0,0.0,2.1031200170516966,2.286200040578842,2.601990071932475,-23.009624838429044,-8.00804917669372,-12.13648102504474,27.406419775230262,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-30,1.4811999949901065,1.6559999358160267,1.4811999949901065,1.554800033569336,214924,0.0,0.0,2.0286000251770018,2.261590039730072,2.5882667382558187,-23.356008366722033,-10.302044599598538,-12.621446379436435,26.11730953592263,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-10-31,1.4996000379121213,1.6376000198701597,1.1684000154092997,1.3524000644683838,261840,0.0,0.0,1.9393600225448608,2.2328400373458863,2.5732400715351105,-30.265652135401776,-13.143799371757812,-13.228460024180825,22.530430105635276,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-01,1.3708000361002421,2.189600148934588,1.3708000361002421,1.913599967956543,623121,0.0,0.0,1.9044000148773192,2.219500035047531,2.564116738239924,0.4830893198568043,-14.196891876303303,-13.439977129471368,45.06058590659332,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-04,2.042399983978271,2.649600050354002,1.9319998722076435,2.299999952316284,138554,0.0,0.0,1.915439987182617,2.2158200323581694,2.558366737763087,20.076847497545916,-13.556157124181025,-13.389272943113074,54.80632728248157,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-05,2.3736000355333084,2.6496002233028486,2.3000001024454857,2.3552000522613525,94476,0.0,0.0,1.9356800079345704,2.213520032167435,2.552233405907949,21.673006003426302,-12.551954362066878,-13.271253834247881,56.00693875586154,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-06,2.391999893618707,2.5943999183626114,2.2999999820737917,2.447200059890747,32701,0.0,0.0,1.9559200048446654,2.216740036010742,2.547480072577794,25.117594473660386,-11.765927755581563,-12.983027428841726,58.009160146032016,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-07,2.3367999466917575,2.447200059890747,2.3367999466917575,2.447200059890747,9581,0.0,0.0,1.9706400156021118,2.220880037546158,2.544106739759445,24.183008591907974,-11.267606431391739,-12.704919064985825,58.009160146032016,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-08,2.447200059890747,2.447200059890747,2.060799992711921,2.447200059890747,52055,0.0,0.0,2.0019200325012205,2.2245600402355192,2.5401200731595357,22.24264806587648,-10.008271465252397,-12.423036070554971,58.009160146032016,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-11,2.3000000993410707,2.4288002014160157,2.2080001831054688,2.2080001831054688,5020,0.0,0.0,2.0644800424575807,2.223180043697357,2.5334500749905904,6.951878327534717,-7.138423254998429,-12.246936869059311,50.53972252061619,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-12,2.3919999891473336,2.3919999891473336,2.263200107840608,2.3736000061035156,21194,0.0,0.0,2.1399200439453123,2.225480043888092,2.529080073038737,10.920032401181397,-3.8445637909787522,-12.004366029655351,54.87204322214879,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-13,2.281600090884426,2.3736000061035156,2.1527999902326003,2.3736000061035156,51403,0.0,0.0,2.2218000411987306,2.229620039463043,2.5227167387803395,6.832296430370222,-0.35073232774656293,-11.618296054078591,54.87204322214879,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-14,2.189600196406793,2.5392000968960944,2.189600196406793,2.5208001136779785,49013,0.0,0.0,2.33864004611969,2.2360600411891935,2.517733405033747,7.789145142730766,4.587533565330469,-11.18757701992591,58.60954869388535,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-15,2.5759999752044678,2.6311999229703624,2.4288001144954148,2.5759999752044678,5955,0.0,0.0,2.4048800468444824,2.2425000429153443,2.5146667381127674,7.115528634557766,7.241025677664526,-10.823171558776075,59.94911085865686,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-18,2.3919999311898503,2.4472000983289193,2.3367999833958755,2.410399913787842,14774,0.0,0.0,2.415920042991638,2.2461800396442415,2.5101434032122296,-0.2284897308505588,7.556829833385958,-10.515867867556663,54.2741492953276,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-19,2.3736000355333084,2.465600171238189,2.3000001024454857,2.3552000522613525,17624,0.0,0.0,2.415920042991638,2.24894003868103,2.503013402223587,-2.5133278274845505,7.4248313178033545,-10.150699285782782,52.49044598197431,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-20,2.3551999276684183,2.391999892265567,2.281599998474121,2.281599998474121,10356,0.0,0.0,2.3993600368499757,2.2498600363731383,2.4967267354329428,-4.907976984165205,6.644857816037181,-9.887613872849277,50.1250219919509,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-21,2.263200107840608,2.4103999721911515,2.263200107840608,2.3736000061035156,13133,0.0,0.0,2.3920000314712526,2.2530800342559814,2.4916667342185974,-0.7692318196342017,6.165781734475572,-9.57538569207725,52.97754062067327,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-22,2.3736000355333084,2.392000018805264,2.3552000522613525,2.3552000522613525,3189,0.0,0.0,2.382800030708313,2.2558400332927704,2.485686735312144,-1.1583002388478183,5.628058529940325,-9.246808890039402,52.33287586595381,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-25,2.355200092186365,2.4104000429379737,2.1712000370025635,2.1712000370025635,24140,0.0,0.0,2.3791200160980224,2.245720034837723,2.479246735572815,-8.739364878131157,5.9401875207449475,-9.419260188362703,46.26939805967244,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-26,2.28160011917353,2.3552000522613525,2.171200000196693,2.3552000522613525,43362,0.0,0.0,2.377280020713806,2.242960035800934,2.4737267355124155,-0.9287912345228794,5.988514408144958,-9.328706214742024,52.229963341989446,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-27,2.189600062939657,2.46560001373291,2.189600062939657,2.46560001373291,14054,0.0,0.0,2.3864800214767454,2.243420034646988,2.4692800680796307,3.315342745136645,6.376870341726651,-9.146796928883612,55.42511667308064,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-28,2.2632000439817253,2.428800106048584,2.2632000439817253,2.428800106048584,41612,0.0,0.0,2.377280020713806,2.245720034837723,2.4654467344284057,2.167186233252758,5.858254093796238,-8.912246876898141,54.125543052739516,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-11-29,2.3367999740802876,2.557599983721068,2.3367999740802876,2.428800106048584,21685,0.0,0.0,2.3625600337982178,2.248020035028458,2.462533402442932,2.803741335786249,5.0951502649001075,-8.71108457662618,54.125543052739516,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-02,2.281600090884426,2.4288001745800694,2.281600090884426,2.3736000061035156,32950,0.0,0.0,2.358880043029785,2.248020035028458,2.4599267343680062,0.6240233841998977,4.9314510668906895,-8.614350028355238,52.004273744239114,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-03,2.3919999599456787,2.4656001105675363,2.3000000458497287,2.3919999599456787,29832,0.0,0.0,2.3625600337982178,2.2507800340652464,2.4577800651391346,1.246102775222657,4.96627826980853,-8.42223574069757,52.67014500117077,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-04,2.4656001406677053,2.502400106755341,2.226400141752972,2.3736000061035156,9870,0.0,0.0,2.371760034561157,2.2526200354099273,2.4568600634733837,0.07757831802317784,5.288952299030271,-8.313050918118318,51.89479782671405,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-05,2.281600085959945,2.3736000009804674,2.2080001539435274,2.226400136947632,12992,0.0,0.0,2.357040047645569,2.2475600361824037,2.4525667309761046,-5.54254098603171,4.871060603529974,-8.358863072080798,46.05397313177623,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-06,2.1527998447418213,2.2999999184893714,2.1527998447418213,2.1527998447418213,56876,0.0,0.0,2.3368000268936155,2.2402000308036802,2.4467400630315144,-7.874023452335872,4.312114755898815,-8.441437459929059,43.42236843278186,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-09,2.3735999701453014,2.520800051610977,2.1711999403844087,2.244800090789795,6753,0.0,0.0,2.344160032272339,2.2379000306129457,2.4413733959197996,-4.238615969671166,4.748201448046338,-8.334381198996981,47.46355037519091,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-10,2.189600088219893,2.46560004219973,2.189600088219893,2.447200059890747,15280,0.0,0.0,2.3533600330352784,2.2434200286865233,2.4387667298316957,3.987491311919545,4.900553750209794,-8.010060935949117,55.06736715887589,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-11,2.318400028668919,2.5392000418442966,2.2816000630305386,2.3919999599456787,14415,0.0,0.0,2.3460000276565554,2.2457200288772583,2.4355467299620313,1.960781404383579,4.465382927961495,-7.7940077580746,52.821937988236314,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-12,2.3920000683819724,2.5760001242602257,2.3920000683819724,2.4840002059936523,12467,0.0,0.0,2.351520037651062,2.2517000317573546,2.4327867309252422,5.633809885580432,4.433095194114393,-7.443591206164481,56.03932433460729,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-13,2.5208001733002816,2.5208001733002816,2.410400052035287,2.4840002059936523,444,0.0,0.0,2.357040047645569,2.257220035791397,2.431253397464752,5.38642347103534,4.422254378013,-7.158174538895551,56.03932433460729,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-16,2.3919999891473336,2.539200072842977,2.189600175665336,2.3736000061035156,35386,0.0,0.0,2.357040047645569,2.2618200302124025,2.4291067322095237,0.7025743357431881,4.209884790180429,-6.886757991278407,51.18165774250306,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-17,2.300000122715444,2.5024001598358154,2.2816001392813288,2.5024001598358154,45931,0.0,0.0,2.3680800676345823,2.2705600380897524,2.427880064646403,5.672109403606533,4.294976917979877,-6.4797280906692025,55.97626365932342,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-18,2.3920000683819724,2.557600140606911,2.355200101075343,2.4840002059936523,65299,0.0,0.0,2.3791200876235963,2.2765400409698486,2.426500064134598,4.408357481223928,4.505962768396844,-6.180095578041207,55.14307017103914,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-19,2.4840001237115232,2.4840001237115232,2.3736000061035156,2.3736000061035156,8184,0.0,0.0,2.3938400745391846,2.2783800423145295,2.422666730483373,-0.8455062913743379,5.067637096547032,-5.955696933191267,50.30480934041936,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-20,2.4288002260993546,2.5576001101381607,2.3736000564519046,2.5024001598358154,15628,0.0,0.0,2.428800106048584,2.2875800490379334,2.419753398497899,3.0303051125508804,6.173338374324525,-5.462265268106017,55.239137064179744,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-23,2.4840001237115232,2.4840001237115232,2.300000073928244,2.3736000061035156,48638,0.0,0.0,2.441680097579956,2.3073600471019744,2.4153067310651144,-2.7882477947834836,5.8213736797031945,-4.469274339973255,49.9030222965804,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-27,2.3367999747516657,2.3367999747516657,2.18960011451225,2.263200044631958,20105,0.0,0.0,2.4232800960540772,2.3234600484371186,2.411320064465205,-6.6059244114117845,4.296180934296797,-3.6436480300914558,45.817506015305305,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2024-12-30,2.1712000264239797,2.2816001467344087,2.0792001089528767,2.1896002292633057,39507,0.0,0.0,2.40304012298584,2.339330053329468,2.4073333978652953,-8.882077818048653,2.7234322735133656,-2.8248411539560525,43.27396208184879,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-02,2.1711999133595246,2.1711999133595246,2.097599983215332,2.097599983215332,12727,0.0,0.0,2.364400100708008,2.3579600512981416,2.4025800625483194,-11.284051181218608,0.27311953000734446,-1.8571706285971232,40.26489856884593,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-03,2.0791999175405884,2.1711998265421295,2.0791999175405884,2.1527998447418213,34411,0.0,0.0,2.331280064582825,2.3639400482177733,2.398440059026082,-7.6558892495373385,-1.3815910289083455,-1.43843539797772,42.833405254317725,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-07,1.8767999734376606,2.1527999308234764,1.8767999734376606,2.097599983215332,41618,0.0,0.0,2.3036800622940063,2.3588800489902497,2.3938400566577913,-8.945690091768196,-2.3400929911579214,-1.4604153510720228,40.93774837757266,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-08,1.8584000692281617,2.0608001050004003,1.8584000692281617,2.0424001216888428,87719,0.0,0.0,2.257680058479309,2.3510600507259367,2.3886267224947613,-9.535449275991347,-3.9718250589896544,-1.5727309510122485,39.07538232016753,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-09,2.04240003492774,2.6311999145755918,1.9319999204030844,2.263200044631958,213266,0.0,0.0,2.2356000423431395,2.3464600503444673,2.3846400558948515,1.2345679802318705,-4.724564050645277,-1.6010804421406468,49.0583509740716,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-10,2.336799888005333,2.502399943972389,2.1159998864976193,2.3183999061584473,148238,0.0,0.0,2.2300800323486327,2.3432400465011596,2.3824933886528017,3.9603903236064366,-4.829211344415748,-1.6475740221817865,51.21071204735454,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-13,2.355200049082432,2.3920000155766727,2.1896001998583485,2.2080001831054688,16352,0.0,0.0,2.2006400346755983,2.337260049581528,2.378506722052892,0.3344549001152478,-5.845306555870432,-1.7341415136201084,46.93910212544247,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-14,2.2448001495997096,2.2816001160939505,2.2080001831054688,2.2080001831054688,33444,0.0,0.0,2.1840800523757933,2.337260049581528,2.374366722504298,1.0952039374040201,-6.553827728033966,-1.5628029390351628,46.93910212544247,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-15,2.300000039085012,2.300000039085012,2.1527999576193366,2.244800090789795,75080,0.0,0.0,2.182240056991577,2.334040051698685,2.3709933876991274,2.866780563292511,-6.5037442093861975,-1.5585592179277674,48.59666562750083,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-16,2.2264001080247224,2.3184000218500844,2.1711999403844087,2.244800090789795,66332,0.0,0.0,2.187760043144226,2.3308200538158417,2.3671600540479023,2.607235095289137,-6.137754411260054,-1.535172924615652,48.59666562750083,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-17,2.263200163240188,2.3920000476997325,2.1896002292633057,2.1896002292633057,3535,0.0,0.0,2.1969600677490235,2.322540056705475,2.362713388601939,-0.3350010131617302,-5.4070106818560895,-1.7003049159608472,46.091824933705425,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-20,2.18960011451225,2.355199957281593,2.1343999475773754,2.263200044631958,56832,0.0,0.0,2.208000087738037,2.314720058441162,2.3591867208480837,2.499997948390936,-4.610491463706203,-1.8848301414199515,49.80668881173513,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-21,2.318399992221739,2.3367999747516657,2.079199999987594,2.263200044631958,53391,0.0,0.0,2.2245600938797,2.311040061712265,2.355660053094228,1.7369704175924907,-3.7420367247329924,-1.8941608880854222,49.80668881173513,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-22,2.2632000161755466,2.3551999276684183,2.2632000161755466,2.281599998474121,43273,0.0,0.0,2.2484800815582275,2.3092000603675844,2.3530533870061237,1.472991341463919,-2.629481085311045,-1.8636775043313167,50.789911288365744,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-23,2.1896001998583485,2.2816001160939505,2.134400030771885,2.2080001831054688,5819,0.0,0.0,2.2429600954055786,2.307360064983368,2.3501400550206504,-1.558650658641714,-2.7910671834503513,-1.8203166209558679,46.83764937342527,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-24,2.226400136947632,2.2632001029558406,2.1711999685902192,2.226400136947632,21689,0.0,0.0,2.233760118484497,2.303680068254471,2.3472267230351767,-0.3294884475714716,-3.035141499616009,-1.855238539734925,47.928568293664576,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-27,2.226400136947632,2.226400136947632,2.152799985586115,2.226400136947632,27470,0.0,0.0,2.2356001138687134,2.300460070371628,2.344313391049703,-0.41152158044762993,-2.819434135730799,-1.870625354336227,47.928568293664576,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-28,2.097599983215332,2.1896001152406663,1.8216000258295162,2.097599983215332,936939,0.0,0.0,2.2245600938797,2.298620069026947,2.340633390347163,-5.707200763587626,-3.2219319819389796,-1.7949552242346098,41.084216521293115,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-29,2.0240000530711395,2.1343999482874283,2.0056000705350914,2.097599983215332,115639,0.0,0.0,2.2098400831222533,2.2921800673007966,2.3366467237472532,-5.079105079329485,-3.59221273028102,-1.9030115247865105,41.084216521293115,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-30,2.097599983215332,2.226400080312763,2.079200000679284,2.097599983215332,109566,0.0,0.0,2.195120072364807,2.2829800665378572,2.3334267218907674,-4.442585641541539,-3.8484783752969793,-2.161912987438209,41.08421652129312,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-01-31,2.171199883917104,2.171199883917104,2.0791999724844223,2.115999937057495,66027,0.0,0.0,2.187760043144226,2.2751600623130797,2.3295933882395428,-3.2800720678488076,-3.841488808483965,-2.3366020096579168,42.54806764058021,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-03,2.116000086250955,2.1712000370025635,2.024000168331607,2.1712000370025635,63084,0.0,0.0,2.1785600423812865,2.2687200605869293,2.3263733883698783,-0.33783807815910194,-3.974047736075377,-2.4782491095871517,46.8172422621482,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-04,2.1159999088583317,2.2631999845340314,2.079199944775679,2.134399890899658,20838,0.0,0.0,2.1656800270080567,2.262740057706833,2.3219267189502717,-1.4443563092564902,-4.289490980998565,-2.5490322653333584,44.4460497812646,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-05,2.1343999475773754,2.263200044631958,2.0975999825175213,2.263200044631958,8852,0.0,0.0,2.1638400316238404,2.25952005982399,2.3185533841451007,4.591837268744561,-4.234528823240575,-2.5461274570944403,53.35140195540527,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-06,2.0975998993408966,2.1527998447418213,2.042399953939972,2.1527998447418213,13221,0.0,0.0,2.1583199977874754,2.2540000557899473,2.314413380622864,-0.25576156692765234,-4.2449004274287585,-2.6103083113293244,46.47455229469163,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-07,2.0791999724844223,2.115999937057495,2.0791999724844223,2.115999937057495,70043,0.0,0.0,2.147279977798462,2.251240050792694,2.309046713511149,-1.4567285619194024,-4.617902606948842,-2.503486065492105,44.419246557870395,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-10,2.115999937057495,2.1343999193440317,2.115999937057495,2.115999937057495,5976,0.0,0.0,2.1362399578094484,2.250320053100586,2.303833379348119,-0.9474600771304692,-5.069505341427022,-2.322794987139,44.419246557870395,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-11,2.116000024676321,2.116000024676321,2.060800075531006,2.060800075531006,25960,0.0,0.0,2.132559967041016,2.245720052719116,2.2989267110824585,-3.3649647662465836,-5.038922172916708,-2.3144129870190517,41.246000913849414,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-12,2.0424000356071876,2.1896001152406663,2.0424000356071876,2.097599983215332,5122,0.0,0.0,2.132559967041016,2.236980050802231,2.295093377431234,-1.6393435291853335,-4.667904111338305,-2.5320680718466426,44.11242971073553,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-13,2.1159999088583317,2.2080000384100518,2.0239999986516994,2.134399890899658,19760,0.0,0.0,2.1362399578094484,2.2305400490760805,2.291566709677378,-0.08613577810224397,-4.227679808111602,-2.663097711429462,46.90217859055221,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-14,2.1896002028137516,2.465600171238189,2.1160000503808263,2.3552000522613525,279929,0.0,0.0,2.160159969329834,2.227320045232773,2.290340042114258,9.028964785049123,-3.0152862875133044,-2.751556350702845,59.85171501683037,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-17,2.299999980772695,2.410399874564141,2.281599998474121,2.281599998474121,82774,0.0,0.0,2.1711999654769896,2.2222600400447847,2.2871200402577716,5.084747363326243,-2.2976642538542045,-2.8358808926214816,55.03368459045678,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-18,2.2448000061035147,2.355199898529054,2.2448000061035147,2.299999952316284,30369,0.0,0.0,2.1877599716186524,2.220420038700104,2.2845133741696677,5.130360832710045,-1.4708958896160715,-2.80555746332014,55.98756003676512,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-19,2.355199957281593,2.355199957281593,2.2448000621020308,2.263200044631958,78236,0.0,0.0,2.1877599716186524,2.214440035820007,2.280526707569758,3.4482792441572063,-1.2048221568336615,-2.897868791906236,53.54127124824033,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-20,2.336799888005333,2.3551998698522185,2.2999999243115616,2.3183999061584473,19610,0.0,0.0,2.204319977760315,2.210300028324127,2.278533373276393,5.175288957551553,-0.2705537930226822,-2.994616877353445,56.604219305805174,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-21,2.3184000569720618,2.3736000061035156,2.300000073928244,2.3736000061035156,30527,0.0,0.0,2.230079984664917,2.210300028324127,2.277460038661957,6.435644569948611,0.8948991579114829,-2.9488996161393524,59.48106699610388,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-24,2.3183999630712697,2.3735999099669924,2.2632000161755466,2.281599998474121,45973,0.0,0.0,2.2466399908065795,2.204780024290085,2.2748533725738525,1.5561019037585275,1.8986005885087305,-3.0803457105670016,53.156140444271635,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-25,2.3183999343872075,2.3919998626709003,2.299999952316284,2.299999952316284,12211,0.0,0.0,2.2705599784851076,2.202940022945404,2.272860038280487,1.2965952941185286,3.069532299353903,-3.0763009669517594,54.20497878375583,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-26,2.3367999740802876,2.428800106048584,2.2632000439817253,2.428800106048584,19364,0.0,0.0,2.3036799907684324,2.2070800244808195,2.2722467044989267,5.431314930092159,4.37682210051883,-2.8679403468417703,60.81835045948074,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-27,2.465600202290098,2.465600202290098,2.3000001314118173,2.3368000984191895,47876,0.0,0.0,2.3239200115203857,2.2107600212097167,2.2705600380897524,0.5542396827323299,5.118601260427555,-2.6337122065420515,54.737733548369235,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-02-28,2.336799945369844,2.410399874564141,2.281599998474121,2.281599998474121,136782,0.0,0.0,2.3165600061416627,2.2153600215911866,2.2687200367450715,-1.509134560505907,4.568105570388916,-2.3519876533748256,51.416120808438116,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-03,2.263200044631958,2.391999922341447,2.2448000621020308,2.263200044631958,81982,0.0,0.0,2.3147200107574464,2.2181200265884398,2.2671867032845814,-2.225753693148809,4.355038636821713,-2.1642097946788583,50.319985304499426,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-04,2.2816000563199395,2.300000039085012,2.2264001080247224,2.244800090789795,189980,0.0,0.0,2.3092000246047975,2.2218000292778015,2.265500036875407,-2.7888417256544984,3.933747149846127,-1.9289343141162274,49.1906264168122,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-05,2.134399974854264,2.3184000218500844,2.134399974854264,2.244800090789795,11774,0.0,0.0,2.307360029220581,2.2268600285053255,2.263813370466232,-2.7113210612354575,3.6149555735340706,-1.6323493112551137,49.1906264168122,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-06,2.2448000621020308,2.281600027161885,2.2448000621020308,2.263200044631958,4798,0.0,0.0,2.301840043067932,2.2268600285053255,2.263353371620178,-1.678656974985723,3.367073529670094,-1.61235729128455,50.479602783681045,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-07,2.3735999398115197,2.3735999398115197,2.226400079572104,2.263200044631958,1958,0.0,0.0,2.2908000469207765,2.2254800319671633,2.2632000386714934,-1.2048193523445059,2.9350977773489664,-1.6666669344205192,50.479602783681045,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-10,2.2632000735548674,2.2632000735548674,2.244800090789795,2.244800090789795,50050,0.0,0.0,2.287120056152344,2.2264000296592714,2.2627400398254394,-1.850360467466868,2.727273880892155,-1.6060179042472515,49.03684637152014,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-11,2.2080001539435274,2.226400136947632,2.2080001539435274,2.226400136947632,11926,0.0,0.0,2.2797600746154787,2.2268600285053255,2.26243337392807,-2.3405944450907596,2.3755442835650453,-1.5723488626311024,47.57258528465514,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-12,2.2080002127575264,2.2080002127575264,2.1896002292633057,2.1896002292633057,4578,0.0,0.0,2.2558400869369506,2.2254800319671633,2.2616667091846465,-2.9363720441543997,1.3642025331025434,-1.6000004364272096,44.69785347079433,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-13,2.281600027161885,2.281600027161885,2.2080000970421767,2.263200044631958,48496,0.0,0.0,2.2484800815582275,2.2259400308132173,2.2621267080307006,0.6546628184284085,1.0126081760062284,-1.5996750796062016,51.066686792354474,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-14,2.15279990303901,2.299999980772695,2.15279990303901,2.281599998474121,1247,0.0,0.0,2.2484800815582275,2.2282400250434877,2.2622800409793853,1.472991341463919,0.9083427407846153,-1.5046773750061895,52.53827436308594,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-17,2.3735999398115197,2.391999922341447,2.263200044631958,2.263200044631958,9336,0.0,0.0,2.2484800815582275,2.2282400250434877,2.261820042133331,0.6546628184284085,0.9083427407846153,-1.484645836729392,50.89011352054648,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-18,2.1896001998583485,2.2080001831054688,2.1896001998583485,2.2080001831054688,1580,0.0,0.0,2.244800090789795,2.2268600285053255,2.261360043287277,-1.639340083569702,0.8056214604790785,-1.5256312184502876,46.20697245628262,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-19,2.244799973088447,2.3183999002896796,2.1527998447418213,2.1527998447418213,11934,0.0,0.0,2.2356000661849977,2.223640024662018,2.260593374570211,-3.703713499368123,0.5378587087088335,-1.6346747860047477,42.04057321127414,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-20,2.2264000204513783,2.2264000204513783,2.134399890899658,2.134399890899658,28366,0.0,0.0,2.2227200508117675,2.2218000173568724,2.2596733729044596,-3.9735170373729054,0.0414093729277044,-1.6760544245784899,40.722476641272394,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-21,2.1160000475247647,2.2264001663525894,2.1160000475247647,2.2080001831054688,12902,0.0,0.0,2.2172000646591186,2.2213400185108183,2.25936670700709,-0.41493240507659107,-0.1863719114228697,-1.6830684624296606,47.77585853393388,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-24,2.2080001831054688,2.2080001831054688,2.2080001831054688,2.2080001831054688,68,0.0,0.0,2.213520073890686,2.2208800196647642,2.259060041109721,-0.24937161629236684,-0.33139772112449567,-1.6900844045827732,47.77585853393388,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-25,2.2816001160939505,2.3000000993410707,2.2080001831054688,2.2080001831054688,15894,0.0,0.0,2.2116800785064696,2.223640024662018,2.2559933761755624,-0.16638461578429972,-0.5378544199107064,-1.434106671376451,47.77585853393388,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-26,2.2080001539435274,2.226400136947632,2.2080001539435274,2.226400136947632,5215,0.0,0.0,2.2153600692749023,2.2268600285053255,2.2540000438690186,0.49834190955437085,-0.5164203893920555,-1.2040822908373585,49.64665657307119,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-27,2.3000000993410707,2.3000000993410707,2.2080001831054688,2.2080001831054688,18089,0.0,0.0,2.2098400831222533,2.2296200335025786,2.2520067115624745,-0.08325941912434719,-0.8871444498663024,-0.9940768801867206,47.802528212999476,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-28,2.208000190837966,2.2264001741495236,2.0424001216888428,2.0424001216888428,36871,0.0,0.0,2.1859200954437257,2.2277800381183623,2.249553378423055,-6.565655078336677,-1.8789980140944524,-0.9678961394530526,35.14833758557489,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-03-31,2.171199912637229,2.263200044631958,2.152799930107302,2.263200044631958,18717,0.0,0.0,2.1859200954437257,2.2300800383090973,2.2489400446414947,3.5353510564870434,-1.9801954237864392,-0.8386175690781414,53.00970740616767,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-01,2.125200082233968,2.263200178730244,2.125200082233968,2.254000186920166,16650,0.0,0.0,2.190520095825195,2.23307004570961,2.2479433794816335,2.897946072987619,-1.9054462696396794,-0.6616418326093791,52.362592113782235,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-02,2.2999999900243275,2.2999999900243275,2.1251999381396565,2.1988000869750977,49120,0.0,0.0,2.195120120048523,2.2314600467681887,2.2472533802191417,0.16764307761406017,-1.62852688186359,-0.7027838333660855,48.53419055934399,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-03,2.125200067688428,2.1896002292633057,2.125200067688428,2.1896002292633057,3655,0.0,0.0,2.200640153884888,2.2323800563812255,2.2463333825270335,-0.5016687804270471,-1.4217965442582046,-0.6211600759861876,47.9055418431675,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-04,2.1988001256090555,2.226400099652881,2.1619999408721924,2.1619999408721924,5667,0.0,0.0,2.19604012966156,2.233530056476593,2.2441100478172302,-1.5500713456731696,-1.678505588331935,-0.47145599436747,45.98130414105599,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-07,2.1528000079811385,2.1619999995788954,2.116000041590109,2.125200033187866,44394,0.0,0.0,2.1877601146698,2.2337600588798523,2.241426714261373,-2.8595494114022566,-2.0593055206260495,-0.34204354453083186,43.47392719029512,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-08,2.1527999116985375,2.2080000781613913,2.1527999116985375,2.1988000869750977,18375,0.0,0.0,2.1868401050567625,2.2372100591659545,2.2402767141660056,0.5469070139458001,-2.2514628835510515,-0.1368873309560213,49.415138457596825,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-09,2.189600170939423,2.226400136947632,2.189600170939423,2.226400136947632,35392,0.0,0.0,2.1868401050567625,2.240430063009262,2.2402767141660056,1.8090043162914502,-2.3919496009850727,0.006845084907899911,51.474864041206445,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-10,2.2264001080247224,2.4380001291681515,2.1159999920891917,2.244800090789795,50649,0.0,0.0,2.190520095825195,2.2431900680065153,2.2398167153199515,2.4779501027198685,-2.3479941772445123,0.15060842538992875,52.853130562397574,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-11,2.1712000264239797,2.290800138481519,2.1712000264239797,2.1896002292633057,6458,0.0,0.0,2.2052401065826417,2.2390500724315645,2.2393567164738974,-0.7092142607351912,-1.5100138342241654,-0.013693398647794747,48.41076466270833,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-14,2.428800234033279,2.428800234033279,2.1896002292633057,2.1896002292633057,11610,0.0,0.0,2.1978801250457765,2.236750078201294,2.2387433846791587,-0.3767219007132312,-1.737787048018138,-0.08903684502233475,48.41076466270833,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-15,2.1896001998583485,2.2080001831054688,2.1896001998583485,2.2080001831054688,2112,0.0,0.0,2.1932801246643066,2.2344500839710237,2.2388967176278434,0.6711435660055135,-1.8425096896123403,-0.19860825297608772,50.03430707067725,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-16,2.2080001831054688,2.3000000993410707,2.2080001831054688,2.2080001831054688,24917,0.0,0.0,2.194200134277344,2.2330700874328615,2.23935672044754,0.6289330044485634,-1.7406508364546043,-0.280733880282472,50.03430707067725,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-17,2.2080001831054688,2.2080001831054688,2.2080001831054688,2.2080001831054688,715,0.0,0.0,2.19604012966156,2.230310094356537,2.239050054550171,0.5446190751419379,-1.5365560502860955,-0.39034233182382516,50.03430707067725,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-22,2.226400207099278,2.226400207099278,2.1712000370025635,2.1712000370025635,21927,0.0,0.0,2.196960139274597,2.225250095129013,2.2379767219225566,-1.172533894062325,-1.2713157912605733,-0.5686666294996398,46.38765892812222,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-23,2.4196000636563753,2.4196000636563753,2.2172000408172607,2.2172000408172607,5152,0.0,0.0,2.206160140037537,2.2236400961875917,2.2386667231718698,0.5004124849946797,-0.7860964631832345,-0.6712310871797593,51.17767968605212,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-24,2.2815999494168016,2.2815999494168016,2.235599994659424,2.235599994659424,8681,0.0,0.0,2.2098401308059694,2.22203009724617,2.244110055764516,1.1656890240317663,-0.5485959193490646,-0.983907115501253,52.987074936341116,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-25,2.410399924342339,2.410399924342339,2.2448000802352976,2.3276000022888184,207,0.0,0.0,2.219960117340088,2.219500094652176,2.250013389190038,4.848730574389892,0.020726409925384118,-1.3561383538631437,60.80815230576807,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-28,2.2356001579761493,2.25400014122327,2.1896001998583485,2.2080001831054688,4497,0.0,0.0,2.216280126571655,2.216280096769333,2.255456723769506,-0.3735964315573505,1.3447001771634415e-06,-1.7369709020485118,49.32108267556894,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-29,2.327600090899445,2.327600090899445,2.226400182314732,2.272400140762329,5964,0.0,0.0,2.2245601177215577,2.2160501003265383,2.2631233910719555,2.1505385563492965,0.3840173736941001,-2.0800143258260606,54.32453915189356,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-04-30,2.419600248336792,2.419600248336792,2.419600248336792,2.419600248336792,30,0.0,0.0,2.2475601196289063,2.219960105419159,2.267340060075124,7.65452844644223,1.243266225477325,-2.089671306490961,63.25457664622115,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-02,2.4103999356754464,2.4103999356754464,2.244800090789795,2.244800090789795,1242,0.0,0.0,2.251240110397339,2.219960105419159,2.26688006122907,-0.2860654257980232,1.409034554351766,-2.0698031895199334,50.602526113866965,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-05,2.235600116813327,2.3735999886258172,2.2172001339049947,2.3092000484466553,10536,0.0,0.0,2.2613600969314573,2.2215701043605804,2.2664967278639474,2.1155388555813883,1.7910752621659618,-1.9822055311638553,54.234445020941884,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-06,2.2448001526296184,2.3552000522613525,2.2448001526296184,2.3552000522613525,11139,0.0,0.0,2.276080083847046,2.2238701045513154,2.2657300611337026,3.4761504648192063,2.3477081322726123,-1.8475262036044011,56.68426440206226,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-07,2.3092000484466553,2.3184000399008213,2.208000142450829,2.3092000484466553,13102,0.0,0.0,2.289880084991455,2.2250201046466827,2.2645800610383353,0.843710707029118,2.9150289567865073,-1.7469003225928776,53.594669005238934,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-08,2.28160011917353,2.3552000522613525,2.208000186085707,2.3552000522613525,60237,0.0,0.0,2.303680086135864,2.2277801036834717,2.26381339430809,2.2364201711665044,3.4069781989208634,-1.5917076343490555,56.16754901935988,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-09,2.391999892265567,2.391999892265567,2.2264000515783984,2.281599998474121,27685,0.0,0.0,2.308280086517334,2.229160100221634,2.264426726102829,-1.1558427505852256,3.549318251651538,-1.5574196097698512,51.26957658186331,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-12,2.2816001324518482,2.327600090899445,2.2080001989356934,2.272400140762329,15333,0.0,0.0,2.302760100364685,2.2312300980091093,2.2635833938916523,-1.3184160867451187,3.205855031240431,-1.4292955130281184,50.67472323232872,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-13,2.263200044631958,2.3092000009567752,2.263200044631958,2.263200044631958,6298,0.0,0.0,2.308280086517334,2.2312300980091093,2.262663394212723,-1.952971051853223,3.453251575307057,-1.3892166322225072,50.04934250201977,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-14,2.2448000621020308,2.300000009691812,2.2448000621020308,2.263200044631958,10357,0.0,0.0,2.307360076904297,2.2307700991630552,2.2605167269706725,-1.9138769329660383,3.4333424932482606,-1.3159215967174394,50.04934250201977,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-15,2.3920000640713353,2.3920000640713353,2.1620000494742797,2.254000186920166,93059,0.0,0.0,2.2908000707626344,2.2305401027202607,2.257833395401637,-1.6064205825791351,2.7015863991364,-1.2088266892040174,49.34312596792304,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-16,2.3552000819228756,2.410400032433934,2.21720020564523,2.3368000984191895,245489,0.0,0.0,2.3000000715255737,2.233760100603104,2.257220063606898,1.6000011195306845,2.9654021890974533,-1.0393298988449895,55.43766532679291,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-19,2.336799888005333,2.336799888005333,2.2539999696943473,2.3183999061584473,12153,0.0,0.0,2.3009200572967528,2.237900102138519,2.256913395722707,0.7596895340306087,2.8160307557076476,-0.8424467514004618,53.88614737211491,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-20,2.2539999897415544,2.3827998638153076,2.2539999897415544,2.3827998638153076,13026,0.0,0.0,2.3036800384521485,2.2441101014614104,2.2577567279338835,3.4344971542280676,2.6545015305597053,-0.6044329888881051,58.28639852441083,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-21,2.327600077353419,2.3644000438973305,2.309200094081463,2.3552000522613525,6763,0.0,0.0,2.308280038833618,2.2477900981903076,2.257603394985199,2.032682891086447,2.6910849323524793,-0.43467762392142917,55.82772314395934,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-22,2.336799916458131,2.355199898529054,2.2907999612808227,2.299999952316284,2966,0.0,0.0,2.3027600288391112,2.250090092420578,2.2571433941523233,-0.11985949418352962,2.3407923352025666,-0.312487977060679,51.177915426007495,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-23,2.3368001132108676,2.3552000968310236,2.254000186920166,2.254000186920166,7589,0.0,0.0,2.300000047683716,2.2512400925159453,2.257833395401637,-1.9999939047773252,2.165915369483199,-0.2920190169531465,47.618633095084796,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-26,2.2632000161755466,2.327599954220557,2.2632000161755466,2.281599998474121,5170,0.0,0.0,2.300920033454895,2.2526200890541075,2.2572200616200764,-0.8396656424327912,2.1441673469701215,-0.20378928240905977,49.87132230419939,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-27,2.3000001158308874,2.3000001158308874,2.2080001989356934,2.272400140762329,16238,0.0,0.0,2.301840043067932,2.2542300879955293,2.255610062678655,-1.2789725504281828,2.11202730927693,-0.06117966513622448,49.11312592656897,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-28,2.281599970245361,2.299999952316284,2.281599970245361,2.299999952316284,2500,0.0,0.0,2.305520033836365,2.260670083761215,2.254536728064219,-0.2394289114415236,1.9839228376274258,0.27204505567146914,51.49556582869538,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-05-30,2.208000021804997,2.2447999856108996,2.208000021804997,2.235599994659424,1111,0.0,0.0,2.3036800146102907,2.259980082511902,2.2529267271359763,-2.9552724127957437,1.933642355370568,0.31307522304074664,46.0749882732237,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-02,2.2448000338769725,2.281599998474121,2.2448000338769725,2.281599998474121,4461,0.0,0.0,2.2981600046157835,2.260670077800751,2.252160060405731,-0.720576726964274,1.658354626054234,0.3778602393600209,50.11431202477865,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-03,2.23560020330001,2.2816001623504,2.226400211489932,2.254000186920166,4843,0.0,0.0,2.2917200326919556,2.2620500802993773,2.251010062297185,-1.645918577911201,1.3116399433849648,0.4904472968426289,47.80072504481308,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-04,2.272399987224722,2.272399987224722,2.2080000497493506,2.2172000408172607,8289,0.0,0.0,2.275160050392151,2.2627400755882263,2.249706729253133,-2.547513506353108,0.5488909193733146,0.5793353491643769,44.82898334631169,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-05,2.272400170540322,2.300000145970556,2.254000186920166,2.254000186920166,8956,0.0,0.0,2.265040063858032,2.265040081739426,2.249936729669571,-0.48740316403330863,-7.894515352390051e-07,0.6712789684567271,48.29098687916254,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-09,2.2080001539435274,2.2540001114537884,2.079200053569697,2.226400136947632,14603,0.0,0.0,2.257680082321167,2.26757008433342,2.250550065437953,-1.3854906024318343,-0.4361497834436404,0.7562603985952625,45.9615232079852,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-10,2.0516000086493076,2.244800042906566,2.0516000086493076,2.1988000869750977,16826,0.0,0.0,2.25216007232666,2.26757008433342,2.25016673207283,-2.3692803192464647,-0.6795826119433788,0.7734250094684353,43.69179213491253,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-11,2.1620000211429926,2.484000168966379,2.1620000211429926,2.272400140762329,71319,0.0,0.0,2.251240086555481,2.268720084428787,2.2487100660800934,0.9399288122673753,-0.7704783852921671,0.8898443000957801,50.685501178535866,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-12,2.299999952316284,2.4380000371932966,2.281599970245361,2.299999952316284,14945,0.0,0.0,2.2540000677108765,2.2701000809669494,2.2479433993498485,2.0408111456768676,-0.70922041680273,0.9856423263819273,53.04091980704115,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-13,2.640000104904175,2.640000104904175,2.5299999713897705,2.5299999713897705,2931,1.9002899,0.0,2.277000069618225,2.278610074520111,2.2483267307281496,11.111106457452363,-0.07065732394889786,1.346928067797057,67.13038565935605,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-16,2.5799999237060547,2.5799999237060547,2.4100000858306885,2.4100000858306885,4367,0.0,0.0,2.2944400787353514,2.2841200709342955,2.2477100630601248,5.036523209576753,0.45181546856398913,1.619871195691522,57.44599411564446,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-17,2.4200000762939453,2.5899999141693115,2.4200000762939453,2.5899999141693115,1934,0.0,0.0,2.3252800703048706,2.293670064210892,2.2495133956273397,11.384428363923197,1.378140936100756,1.9629431266950887,65.488523857319,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-18,2.569999933242798,2.5999999046325684,2.569999933242798,2.569999933242798,2951,0.0,0.0,2.356880044937134,2.3027200579643248,2.250076727072398,9.042458005593943,2.352000486793353,2.339623811869822,64.0402606714541,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-19,2.569999933242798,2.569999933242798,2.440000057220459,2.5,25364,0.0,0.0,2.385160040855408,2.310020053386688,2.2502100586891176,4.814769540722566,3.2527850725173604,2.6579738396695927,59.11286930813827,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-23,2.549999952316284,2.5999999046325684,2.4100000858306885,2.4100000858306885,5606,0.0,0.0,2.40076003074646,2.3159900546073913,2.2505133926868437,0.3848804114485132,3.66020467015516,2.9094100098811797,53.421589646731405,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-24,2.4200000762939453,2.4800000190734863,2.4000000953674316,2.4100000858306885,6648,0.0,0.0,2.419120025634766,2.320810055732727,2.2497433920701346,-0.37699410146812773,4.236019645778388,3.158878648697773,53.421589646731405,,-0.778,0.0,0.0,-0.47733003,,0.6666667,,CombiGene AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
